


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 9/16, 9/50, 49/00	A2	(11) International Publication Number: WO 88/ 07365 (43) International Publication Date: 6 October 1988 (06.10.88)
<p>(21) International Application Number: PCT/US88/01096</p> <p>(22) International Filing Date: 30 March 1988 (30.03.88)</p> <p>(31) Priority Application Number: 033,432</p> <p>(32) Priority Date: 1 April 1987 (01.04.87)</p> <p>(33) Priority Country: US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 033,432 (CIP) Filed on 1 April 1987 (01.04.87)</p> <p>(71)(72) Applicant and Inventor: RANNEY, David, F. [US/US]; 3539 Courtdale Drive, Dallas, TX 75234 (US).</p>	<p>(74) Agent: HODGINS, Daniel, S.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).</p> <p>(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	

(54) Title: BIODADHESION DRUG CARRIERS FOR ENDOTHELIAL AND EPITHELIAL UPTAKE AND LESIONAL LOCALIZATION OF THERAPEUTIC AND DIAGNOSTIC AGENTS



(57) Abstract

This application describes the preparation and in vivo testing of surface coatings and matrix materials, which when applied to or caused to comprise the carriers for drugs and diagnostic agents, and administered in a fashion that allows efficient vascular access, causes the carriers to recognize determinants present on normal or focally diseased endothelium, and induces the following in vivo effects: (1) rapid, partial or total endothelial envelopment of the drug (diagnostic) carrier; (2) sequestration of the carrier and protection of the entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the carrier still invaginates into the vascular compartment; (3) acceleration of the carrier's transport across and/or through the vascular endothelium or subendothelial structures into the tissue compartment (interstitium); and (4) improvement of the efficiency with which the drug (or diagnostic) carrier migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total drug dose is required to obtain the desired effect relative to that required for standard agents. Analogous tissue uptake is described for transepithelial migration into the lungs, bladder and bowel.

FOR THE PURPOSES OF INFORMATION ONLY.

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

5

-1-

10

BIOADHESION DRUG CARRIERS FOR ENDOTHELIAL AND
EPITHELIAL UPTAKE AND LESIONAL LOCALIZATION
OF THERAPEUTIC AND DIAGNOSTIC AGENTS

15

Until recently, the localization of intravascular drugs in body tissues has depended on chemical partitioning across microvascular barriers into the tissue compartments of multiple body organs. This resulted in only 0.01% to 0.001% of the injected dose actually reaching the intended targets. Approximately 20 years ago, drugs were entrapped in liposomes and microspheres. This modified the initial biodistributions and redirected them to phagocytes in the reticuloendothelial organs: liver, spleen and bone marrow.

In 1978, the present inventor and coworkers (Widder, et al., Proc. Am. Assn. Cancer Res., V. 19, p 17 (1978)) developed a means to co-entrap drug plus magnetite in microspheres which could be injected intravenously and localized magnetically in the tissue compartments of nonreticuloendothelial target organs (e.g., lung and brain). Magnetic capture was accomplished by selective dragging of the particles through the vascular endothelium into normal tissues and tissue tumors positioned adjacent

to an extracorporeal magnet of sufficient strength (0.5 to 0.8 Tesla) and gradient (0.1 Tesla/mm). Although this technique was highly efficient and deposited between 25% and 50% of an injected dose in the desired target tissue, it was also a very complicated approach which had the following major disadvantages: 1) restriction of use to specialized medical centers; 2) permanent disposition of magnetite in target tissue; 3) focal overdosing of drug due to inhomogeneity of the capturing magnetic field; and 4) application to a very limited number of therapeutic agents. In the process of studying magnetic targeting, however, it was learned that slow (controlled) release of toxic drugs from entrapment-type carriers (microspheres) protected the normal cells within the local tissue environment from drug toxicity and still gave effective treatment of tumor cells and microorganisms.

When monoclonal antibodies became generally available for animal and clinical research, it was hoped that antibody-drug conjugates would limit the biodistribution of toxic agents and cause them to become deposited in foci of disease (tumors and infections) which were located across the microvascular barrier within target tissues. Unfortunately, most monoclonal antibodies were (and are still) obtained from mice, making them immunologically foreign to human recipients. Conjugation of drugs at therapeutically relevant substitution ratios makes the monoclonal antibody derivatives even more foreign and impairs their binding specificities. Hence, antibody-drug conjugates are cleared rapidly by the liver, in a fashion similar to that for liposomes. Importantly, their localization in most solid tumors is even further impaired by the presence of a partially intact microvascular barrier which separates the tumor tissue (interstitium) from the bloodstream. This allows only about 1% to 7% (at best) of the injected dose to reach nonreticuloendothelial

targets. Selected lymphomas and leukemias provide exceptions to this rule because of a greater natural breakdown of this vascular barrier. However, for the vast majority of solid tumors and infections, a general-purpose method is still needed to deliver drugs efficiently across microvascular barriers in a depot (controlled release) form.

Such a form of drugs is necessary in order to protect vascular endothelium and normal tissue cells from the toxic effects of drugs, protect drug from endothelial and tissue metabolism during transit, and make drug bioavailable at a controlled therapeutic rate within the target tissues and tissue lesions.

15

Active endothelial transport has been demonstrated for small molecules (e.g., glucose and insulin), however, no studies other than those of the present inventor have shown such transport for larger molecules or molecules carried in a cargo format. Present examples show that transendothelial migration of particles and molecular aggregates larger than ca. 2 nm in diameter are accelerated by the application of surface coatings which bind multiply to receptors or antigens which are either synthesized by endothelium or are synthesized at other sites but become tightly associated with the endothelial surface. (Ranney, Biochem. Pharmacology, V. 35, No. 7, pp. 1063-1069 (1986)).

30 The present invention involves a composition of matter comprising a carrier having a surface, at least two molecules of drug or diagnostic agent contained by the carrier and a multivalent binding agent specific for endothelial surface determinants. At least a portion of said binding agent is attached to the surface of the carrier. The carrier preferably has a size of between

35

about 1 nanometer (nm) and about 250 micrometer (um). The binding agent is one which bioadheres to endothelial surface determinants and induces envelopment of the carrier by endothelial cells of a vascular wall and transfer across said wall to proximal tissues. The term bioadhere as used herein means interactions characteristically encountered in biological systems involving multiple molecular and usually noncovalent bonds.

10

The carrier involved in the method and composition of matter of the present invention preferably comprises one or more of macromolecules, microaggregates, microparticles, microspheres, nanospheres, liposomes and microemulsions. The endothelial surface determinants are those characteristic of endothelial tissues, some of which may be defined further as being enhanced in quantity when proximal to tissue lesions. These endothelial surface determinants comprise, for example, Factor VIII antigen, Interleukin I receptor, endothelial thrombodulin, endothelial tissue factor, subendothelial tissue moieties, fibrin D-D dimer and GP 2b/3a glycoprotein complex.

The multivalent binding agent of the present invention is preferably a substance such as heparin, a heparin fragment or Ulex Europaeus I lectin. In certain cases an antibody directed toward endothelial surface antigens could be utilized as the multivalent binding agent. The multivalent binding agent of the present invention may also be directed toward subendothelial tissue moieties such as laminin, type IV collagen, fibronectin or a fibronectin fragment chemotactic for monocytes. These subendothelial moieties may, for example because of lesion formation, be exposed to vascular fluids and thus bind and/or envelop the composition of matter of the present invention. The composition of matter of the

present invention may comprise a multivalent binding agent which binds to vascular endothelium via endothelial surface receptors, surface enzymes, substances which coat the endothelial surface or substances which immediately
5 underly the endothelium and may be deposited, exposed or altered in normal vascular endothelium or proximal to foci of tissue or endothelial disease.

The composition of matter of the present invention
10 may be used in a procedure involving binding of a sample thereof to endothelia and an induction of the endothelia to totally or partially envelop the bound sample in, for example, less than 10 to 15 minutes. The interaction of the composition of matter of the present invention with
15 endothelia may produce an induction of the endothelia to undergo transient separation or opening, thereby exposing subendothelial determinants for which the composition of matter may also have binding affinity. The composition of matter of the present invention may, by interaction with
20 endothelia, produce an induction of total or partial sequestration of an associated drug or diagnostic agent at an early time when it still resides in or protrudes into an associated vascular lumen.

25 The composition of matter of the present invention may be characterized by the interaction of a sample thereof with endothelia which produces an acceleration of transport of the sample across at least one of associated vascular endothelial and/or subendothelial structures into
30 a proximal tissue compartment. The interaction of a sample of the composition of matter of the present invention with endothelia may result in improvement of the efficiency with which an associated drug or diagnostic agent migrates across the endothelia and associated
35 structures such that a reduced total dose of drug or diagnostic agent may be administered to obtain effects

comparable to a significantly higher dose of free drug or diagnostic agent.

5 The composition of matter of the present invention is preferably a microsphere in certain embodiments. Such a microsphere comprises a matrix and is most preferably between 0.2 and 250um in diameter. The matrix is preferably a carbohydrate and may be a carbohydrate such as heparin which also has multivalent binding
10 capabilities. Dextran is also a preferred matrix and may preferably be coated with a multivalent binding agent such as heparin, for example. In this latter case the composition of matter of the present invention is preferably about 10% (w/w) heparin.

15

A drug or diagnostic agent comprised in the composition of matter of the present invention may be an antifungal polyene macrolide such as amphotericin B. The amphotericin B or other hydrophobic drug or diagnostic
20 agent may be in a cyclodextrin complex. The drug or diagnostic agent such as amphotericin B may be in a controlled-release form, for example within internally entrapped micelles of pluronic F68 block copolymer, polyoxypropylene-polyoxyethylene.

25

The composition of matter of the present invention may preferably comprise a microsphere carbohydrate matrix and, as a multivalent binding agent, an exposed or covert lectin capable of binding endothelial surface
30 determinants, enzymes, epi-endothelial or subendothelial substances.

The composition of matter of the present invention, in one preferred embodiment, comprises a carrier having a
35 surface, at least two molecules of drug or diagnostic agent contained by the carrier, a multivalent binding

agent specific for endothelial determinants, at least a portion of said binding agent being attached to the surface of said carrier and a removable coating which renders the multivalent binding agent unexposed to external contacts. The removable coating is a coating subject to removal by a triggering event. The triggering event is a condition such as lowered pH, temperature alteration, contact with normal endothelia, contact with abnormal endothelia, altered enzyme levels or physical changes induced by application of external forces such as radiofrequency, ultrasound, magnetism or electricity.

The composition of matter of the present invention, with or without a removable coating may be one in which the multivalent binding agent is a lectin with affinity for endothelial, epi- or subendothelial determinants. In one preferred embodiment the lectin is Ulex Europaeus I lectin and the removable coating is fucose, fucosyl albumin or albumin-fucosyl amine.

The composition of matter of the present invention may comprise a multivalent binding agent which is an antibody with affinity for endothelial or subendothelial binding sites. The multivalent binding agent of the present invention also may be a substrate for an endothelial or epi-endothelial enzyme; a peptide, for example benzoyl-phenylalanyl-alanylproline, which has a substrate affinity for endothelial angiotensin converting enzyme.

In another preferred embodiment of the present invention, the drug or diagnostic agent and the multivalent binding agent are the same and comprise a molecular microaggregate of 1 to 200 nanometers in molecular diameter, most preferably where the drug or diagnostic agent and the multivalent binding agent are the

same and comprise a molecular microaggregate of heparin of about 1 to 200 nanometers in molecular diameter.

5 The composition of matter of the present invention is, in a preferred embodiment, in a pharmaceutically acceptable solution suitable for intravascular or other parenteral injection.

10 Methods of use of the composition of matter of the present invention comprise administration to an animal of a carrier having a surface, at least two molecules of drug or diagnostic agent contained by the carrier and a multivalent binding agent specific for endothelial surface determinants, at least a portion of said binding
15 agent being attached to the surface of said carrier as described above. The above composition of matter is preferably contained in a pharmaceutically acceptable carrier. The multivalent binding agents are selected for the particular targeted sites, most especially the
20 endothelia. The drug or diagnostic agent is selected according to the particular lesion being treated or the diagnostic method being utilized. The carrier may be a natural or synthetic polymer.

25 Figure 1 is a lung tissue section stained with PAS, which is representative of the test mice sacrificed 2-5 minutes after intravenous injection of the unheated, acetone-stabilized heparin microspheres.

30 Figure 2 is a lung tissue section stained with PAS, which is representative of the test mice sacrificed 10 minutes after intravenous injection of the same heparin microspheres as in Figure 1.

35 Figure 3 is a lung tissue section stained with PAS, which is representative of the test mice sacrificed 2-5

minutes after intravenous injection of the fucose-blocked, Ulex Europaeus agglutinin I-coated spheres of Example 4.

Figure 4 is a lung tissue section stained with a
5 reticulin stain, which is representative of the test mice sacrificed at 10 minutes after intravenous injection of the identical fucose-blocked, Ulex Europaeus agglutinin-coated spheres of Example 3.

10 Figure 5 is a lung tissue section stained with PAS, which is representative of the test mice sacrificed 20 minutes after intravenous injection of the identical fucose-blocked spheres of Examples 3 and 4.

15 Figure 6 is a representative example of control microsphere (M_c) of plain agarose which is present within a lung microvessel (V) 10 minutes after intravenous injection.

20 The present invention involves nontoxic, biodegradable small microspheres (less than about 0.2-100 micrometers (μm) in size) and microaggregates (1-200 nanometers, nm) comprising (or coated with) endothelial-binding substances. These substances induce the following
25 serial steps upon intravenous injection of particles into test rodents: 1) endothelial bioadhesion; 2) rapid (2-minute) endothelial envelopment (partial or total) of the particles (microaggregates); 3) a facilitated (accelerated) migration of intact drug-carrier particles
30 across microvessels into the tissue compartment; (which is largely complete within 10 to 20 minutes of injection); and 4) delayed release of drug (or diagnostic agent) from a microsphere formulation of envelopment carrier which is known to correlate with controlled bioavailability of drug
35 within the target tissue (lesion) in vivo.

The examples presented herein include three major approaches for compositions of matter serving as formulation carriers for efficient, nonmagnetic drug localization in normal and diseased tissues, either in the presence or absence of potentially competing receptors on the surfaces of circulating red cells, white cells or platelets. These approaches are as follows: 1) microparticles (and microaggregates) comprising (and coated with) heparins which bind to the complementary heparins and heparan sulfates present on normal endothelium throughout the body (lung and brain binding are documented below); 2) microparticles with surface-conjugated Ulex Europaeus agglutinin I, a glycoprotein which binds to factor VIII antigen present on the luminal surface of endothelium and which is reported to be present at increased densities in foci of disease (Loesberg et al., Biochem. Biophys. Acta, V. 763, pp. 160 (1983)); 3) microparticles with surface-conjugated Ulex Europaeus agglutinin I, in which the factor VIII antigen-binding site is of the Ulex agglutinin blocked noncovalently by addition of the sugar hapten, L-fucose, in order to render this site covert (reversibly coated) and prevent its binding of potentially similar receptors on circulating red blood cells. Surface-coated microcarriers may also make use of interleukin 1 and its receptor sites induced by disease on the surface of vascular endothelium (Libby et al., Fed. Proc., V. 45, p. 1074 (1986)).

For these examples, initial morphometric data indicated that at least 25% of the injected carrier migrated across microvessels of the first target organ encountered, namely, lungs by the intravenous route, and brain by the carotid arterial route. Hence, these new carriers are (by a factor of five) the most efficient general-purpose drug delivery devices described. In one example, microparticles (0.1 to 0.6 um) of amphotericin-

cyclodextrin which released the drug at a very slow rate (t 1/2 greater than about 36 hours) were entrapped within larger (5 to 25-um) macroparticles of a more rapidly degrading heparin matrix (t 1/2 about 15-minutes in
5 flowing blood and blood amylase). Such a hybrid microcarrier allows for both slow release of the extravascular drug within tissues and rapid degradation of the fragments remaining within microvessels. The latter property minimizes transient disruption of microvascular
10 blood flow which might otherwise occur upon infusion of therapeutically relevant doses of the microcarrier. This formulation comprises a true "cellular drug carrier" because it mimics the morphology and function of white blood cells (living macroparticles), which migrate into
15 tissue lesions and release lysosomal enzymes and lymphokines (biopharmaceuticals) as a controlled rate from their intracellular granules (living microparticles).

From the results of the present invention and known
20 biological functions and relationships involving endothelial and related binding substances, the following extensions of the present technology involving multivalent binding agents and variations thereof appear readily accomplished. These extensions may be grouped as relating
25 to multivalent binding agents as follows:

GROUP I. Substances which bind to native endothelium such as:

- 30 1. Heparin
2. Heparan sulfate
3. Heparin fragments and synthetic analogues which bind antithrombin III (pentasaccharides hexasaccharides and oligosaccharides)
- 35 4. Ulex Europaeus I agglutinin (binds factor VIII antigen)

5. F-met-leu-phe
6. t-boc-leu-phe-leu-phe
7. Benzoyl-phe-ala-pro (BPAP, binds angiotensin converting enzyme)
- 5 8. Other inhibitors of angiotensin converting enzyme
9. 5'-nucleotides (bind 5'-nucleotidase)
10. Inactive congeners of the biogenic amines, 5-hydroxytryptamine and norepinephrine
11. Insulin and inactive insulin analogues
- 10 12. Transferrin
13. Prostaglandins E, F and stable congeners
14. Peptide substrates and inhibitors of tissue plasminogen activator (tPA)
15. Albumins and glycosylated albumins
- 15 16. Cationic ferritin
17. Low density lipoproteins (LDL)
18. Hirudin-inhibited thrombin (binds thrombomodulin)
19. Antibodies against (and receptor molecules for):
Surface carbohydrates of:
 - 20 1. Central lymph-mode endothelium (MEL-14 and MECA-367 Ab's)
 2. Peripheral lymph-mode-endothelium (MECA-79 Ab)
 3. Panendothelium (MECA-325)
 - 25 4. Capillary-level endothelium with organ specificity (e.g., lung, liver, and brain endothelial antibodies)
20. Negatively charged polysaccharides or oligosaccharides such as, for example:
 - 30 a. Dextran sulfate
 - b. Dermatan sulfate
 - c. Chondroitin sulfate, and
 - d. Hyaluronic acid

GROUP II. Substances which bind preferentially to activated and diseased endothelium

1. Ulex Europaeus I agglutinin
2. Ulex Europaeus I agglutinin, reversibly blocked
5 with:
 - a. Fucose
 - b. Fucosyl albumin
 - c. Albumin-fucosyl amine
 - d. Other neoglycoproteins
 - 10 e. Aminated carbohydrates
3. Cytoadhesion molecules with affinity for activated endothelium:
 - a. ICAM-1
 - b. LFA-1
 - 15 c. Mac-1
 - d. P50
 - e. VLA molecules
4. Interleukin I
5. Antibodies against (and receptor molecules for):
 - 20 a. Endothelial leukocyte adhesion molecule, ELAM (H4/18 and H 18/7 Ab's)
 - b. Endothelial tissue factor, tf
 - c. Endothelial-associated, fibrin D-D dimer
 - d. Class II histocompatibility antigens, Ia and
25 HLA-Dr
 - e. Fc receptors
 - f. Mo3e surface antigens
 - g. Factor VIII antigen
 - h. Glycoprotein IIB
 - 30 i. Glycoprotein IIIa
 - j. Glycoprotein IIB/IIIa complex
 - k. Il-1 receptor of endothelium
 - l. "Extra domain" of fibronectin, ED

GROUP III. Substances which bind to subendothelial molecules and structures exposed by endothelial activation and disease:

1. Ricinus communis agglutinin I (binds to basement
5 membrane molecules)
2. Antibodies against (and receptor molecules for):
 - a. Fibronectin
 - b. Fibronectin fragments (e.g., monocyte
chemotactic fragment)
 - 10 c. Laminin
 - d. Intercellular adhesion molecules (e.g., ICAM-1)
 - e. Type IV collagen
 - f. Basement membrane molecules (anti-GBM
antibody).

15

An additional aspect of the present invention, is the formulation of microcarriers in which the endothelial-binding ligands are themselves coated by an outer
20 protective layer of polymeric fucose derivatives. Such derivatives include, for example, the neoglycoproteins, fucosyl albumin and albumin fucosyl amines. Such protective coatings could be used to achieve semiselective targeting of tissue lesions following systemic intravenous
25 administration of such composite carriers. By appropriate selection of the isoelectric and thermodynamic properties of these surface polymers, selective uncoating could be induced at sites of lowered pH which typically exist in microvessels which supply tumors and sites of chronic
30 infection.

Selective uncoating is possible because glycoproteins and other surface polymers each exhibit their lowest solubility at their isoelectric point (pKI) and become
35 increasingly soluble (unstable as surface coatings) as the pH is lowered below the pKI. Hence, the optimal

isoelectric point for uncoating polymers in the body is at about blood pH (7.35). According to present art, the rate of such uncoating could be accelerated, for example, by incorporating a triggerable form of glucose oxidase in the microcarrier matrix which would generate gluconic acid and further protonate the surface polymer at lowered pH.

An important consideration in employing these technologies involves minimizing the rapid reticuloendothelial clearance of particles. Just recently, this has become feasible to accomplish by maintaining a small (ca. 50 nm) particle size and coating the particles with combination hydrophilic-hydrophobic block copolymers, such as the tetronic block copolymer 908, the pluronic copolymer F68 and others. A second method for inducing selective uncoating in lesional microvessels, is the use of surface coatings which are degraded by lesional degradative enzymes. These enzymes include serine esterases (e.g., tissue plasminogen activator and other enzymes of the coagulation cascade), and lysosomal enzymes (e.g., acid esterases and beta glucuronidase). A third method for selective uncoating involves the potential sensitivity of protective surfaces to external physical energy, such as occurs with melting of surface lipids by regional hyperthermia and disruption of hardened surface coatings by high-frequency ultrasound.

The endothelial envelopment-transport coatings documented below are adaptable for use with all synthetic and natural, solid (Matrix) and deformable (lipid and hollow) transvascular microcarriers, including microspheres, liposomes, artificial membranes, microvesicles, and hydrophilic and hydrophobic microemulsions, wherein the matrix and/or coating materials may be comprised of carbohydrates, oligo- or monosaccharides, proteins or peptides, lipids, alkyl or

alkenyl chains, or bicompatible synthetic polymers. The drug or diagnostic agent carriers of the present invention may vary in complexity, including, for example:

5 1) single chain polymers;

 2) molecular microaggregates in which the molecular carrier/aggregate comprises both the endothelial binding moiety and the backbone for linking prodrug moieties;

10

 3) complex supramolecular carrier comprising multiple matrix material and/or serial coatings, with a major criterion of novelty being that multiple (two or more) endothelial binding sites are engaged by the carrier
15 material or microcarrier surface in order to activate the endothelial cellular processes required for rapid envelopment (thereby sequestering the spheres from vascular degradation and drug from downstream release during transendothelial migration) and transport of the
20 carrier.

 This invention is not considered to be constrained by prior art involving the formulation of microcarrier matrices from any of the presently proposed materials
25 providing that the said materials were not previously recognized and documented in vivo as undergoing multiple endothelial binding and inducing rapid endothelial envelopment, and producing accelerated extravasation of macromolecules, microaggregates and microparticles in
30 either the first microvascular bed encountered, or potentially (as proposed) semiselectively at foci of disease following systemic intravenous administration.

 Endothelial-envelopment carriers may be formulated
35 and stored in either the dry or fluid state, to which may be added, for example, pharmaceutically acceptable

appropriate stabilizers, osmotic agents, colorings, flavorings, and physiologic solutions which render them appropriate for intravascular and intracavitary injection. The present invention is envisioned as most particularly
5 applying to the vascular targeting phase of any future device (see below) which is developed for the efficient first-step transit across the external body barriers (e.g., gastrointestinal tract; oral, nasal rectal, bladder or vaginal mucosa; skin, cornea or sclera).

10

The present application documents that drug carriers which comprise microencapsulation spheres with surface adhesion properties were selectively taken up into tissues by endothelial bioadhesion and by induced transendothelial
15 migration, into the tissue interstitium. The present application additionally documents that drugs controlled by such carriers, are deposited in selected target tissues, such as lung, in exact proportion to the deposition of drug carriers. It is now further
20 established that soluble drug-carrier complexes (as well as formally microencapsulated drugs) give comparable tissue uptake of drugs, under conditions in which the drug alone is not taken up. It is now further established that the same and similar carriers are taken up by the
25 transepithelial route in the lungs, gastrointestinal tract and bladder. Finally, it is established that the same and similar carriers undergo preferential lesional concentration in tumors and niduses of pulmonary infection.

30

The unique aspect of drug carrier technologies established by the present application are that these novel carriers afford high-efficiency tissue uptake and localization of drugs (and diagnostic agents), in
35 particular, when the drugs are controlled by nonembolizing (less than 3-4 um), as well as embolizing (5-250 um)

carriers. Other unique features are that these carriers
a) are formulated of water-soluble, biocompatible and
biodegradable materials, and b) afford widespread
percolation throughout tissue intersitium (and lesional
5 gels) in a fashion which is not possible for hydrophobic
carriers (e.g., liposomes). Finally, the carriers of
principal embodiment interact with their initial sites of
cellular uptake (endothelial and epithelial cells) based
on carbohydrate-carbohydrate binding, as well as by
10 protein-carbohydrate (and potentially peptide-carbohydrate
and peptide-protein binding), and they do so in such a
fashion as to produce multivalent binding, which leads to
an induced, active endothelial (or epithelial) envelopment
and transendothelial (or transepithelial) transport of
15 both the carriers and drugs controlled by the carriers.
This preferably involves either transcytosis (process
occurring across one endothelial or epithelial cell,
exclusively for the smaller 0.02 μm - 10 μm agent-carrier
complexes) or endothelial (epithelial) migrational
20 overgrowth of the carriers, leading to envelopment,
exclusively of the larger (10-100 μm) particulate drug
carriers.

The minimal requirements for novelty are that
25 multivalent binding to cells (or adjacent matrix
substances) must occur, in order to induce:

- a) active extravasation (or epithelial transport)
of the drug-carrier couple, wherein such
30 transport is significantly accelerated relative
to that obtained for uncoated (uncontrolled)
particles or drug-carrier complexes; this
acceleration being of such a degree that
transcellular transport of nonembolizing as well
as embolizing particles (complexes) is completed
35 within twelve minutes of endothelial/epithelial

5 contact (typically in less than 5 minutes),
under in vivo conditions of microvascular blood
flow and/or cavitory fluid flow, air flow, or
enteric flow (in microvessels, bladder, lungs,
bowel, or other body cavities, respectively) and
further,

10 b) that the carriers must control the delivery of
multiple (at least two) molecules of drug, in
order to distinguish them from naturally
transported simple hormones, proteins, peptides,
and hybrid conjugates of two low-molecular-
weight drugs.

15 The present continuation-in-part expands on examples
initially provided and shows that certain of the drug-
carrier systems (specifically, heparin-amphotericin
microspheres) undergo not only primary uptake into normal
tissues by accelerated transendothelial migration, but
20 also secondary, subregional concentration within foci of
disease involving the tissues (pulmonary infections; and
pulmonary, hepatic, and subcutaneously implanted tumors).
Such lesional concentration is based on:

25 a) the initial binding of heparin and heparin
fragments to constitutive endothelial receptors
(which comprise antithrombin III,
thrombomodulin, heparin cofactor II, and
others);

30 b) coincident or subsequent binding of heparin (or
heparin fragments) to sites (tissue components)
exposed (induced) by disease, comprising one or
more of the following: epi-endothelial platelet
35 factor 4 (and others), subendothelial
fibronectin split products (e.g., 33,000 dalton

proteolytic fragment), type IV collagen (and its subunits), type I collagen, laminin and others; and

- 5 c) finally, the active cellular uptake preferentially by transformed and malignant cells, of negatively-charged and neutral polycarbohydrates: specifically heparin, dextran and modified dextran microspheres which
10 contained amphotericin B or heparin-cis-platin complexes. This cell biological uptake mechanism has been documented for hepatocellular carcinoma cells, and it putatively occurs for
15 other transformed and malignant cells.

15 Although the preferred embodiment describes a surface coating of heparin, alternative carriers (and surface coatings and drug-complexing agents), such as heparin fragments, tridodecyl methylammonium chloride heparin,
20 hereinafter referred to as TDMAC heparin, the dermatan sulfates and their fragments, and other glycosaminoglycans (GAG's), also serve to bind to constitutive and induced heparin cofactor II. The 8-12 unit fragment of dermatan sulfate binds heparin cofactor II without activating it.
25 Unlike native heparin, neither dermatan sulfate nor its 8-12 unit fragment inhibits the constitutive endothelial surface coagulant, antithrombin III. This is also true of the shorter, semisynthetic fragments of heparin. Hence, dermatan sulfate and the short fragments of both heparin
30 and dermatan sulfate, are envisioned as having even less anticoagulant activity than does native heparin (whose minimal anticoagulant activities are still acceptably low in this regard, when the heparin is incorporated into drug microspheres and complexes.

Additionally, endothelial and para-endothelial receptors are envisioned as being useful for selective organ uptake and secondary tissue localization in regions (foci) of disease. These include: the endothelial

5 adhesion determinants induced by interleukin 1 (and by other cytokines and lymphokines), platelet activating factor(s) (PAF's), the surface coagulation factors, IIa, Va, VIIIa, IXa, Xa, XIa, von Willibrand factor (vWF), and endothelial tissue factor; and types IV and I collagen and

10 the fibronectin fragments exposed by various disease processes (which can promote the attachment of metastatic tumor cells). Additionally, complementary substances are envisioned as useful in formulating surface coatings (complexes) for binding (and selective localization) at

15 one or more of the preceding lesional sites. These include: peptide-11 (an anti-attachment substance for tumor cells); monoclonal antibody AHB-2 (and its Fab fragment) and fibronectin-binding polypeptide (the latter two of which bind the 33,000 dalton proteolytic fragment

20 of fibronectin); agents which bind alternative fragments of fibronectin; fibronectin itself; fibronectin derivatives; and other complementary substrates; drugs; binding substances and their derivatives).

25 Epithelial uptake of the drug carriers (particularly the heparin-amphotericin B microspheres) are further tested in the present application and shown to be taken up via the intratracheal, gastrointestinal and intracystic (bladder) routes. Such epithelial uptake is tested for

30 microspheres which comprise minor modifications of the drug carriers described in the present application. These formulations are as follows: microspheres with entrapped iron oxide, Fe_3O_4 ; and microspheres with heparin matrices, and heparin-coated dextran and albumin matrices, which

35 contain entrapped ionic iron (Fe^{+3}). The novel examples of epithelial uptake shown below, provide the rationale

for administering bioadhesion drug carriers by the intratracheal route (inhalation), gastrointestinal routes (oral and rectal), cystic route (bladder and prostate), oral route with gastrointestinal uptake leading to
5 systemic distribution (via the bloodstream) and to secondary targeting of the carriers to organs and lesions. These examples provide the further rationale for administering such drug carriers by injecting them directly into other body cavities, such as the peritoneum,
10 uterine tubes, pleura, ventricles of the brain and spinal cord, epidural and subdural spaces, tumors and abscess, subcutaneous tissue, muscles, medullary cavities of bone, and joint spaces.

15 Endothelial uptake is described for a new physical formulation, namely a macromolecular complex between heparin and cis-platin (an antitumor drug). Selective high-efficiency pulmonary uptake of this drug and carrier complex is documented in the present application following
20 bolus intravascular injection of the complexed agent, as is the absence of liver uptake, which typically occurs for the drug alone. The absence of endothelial injury by heparin-cis-platin (at an otherwise highly toxic concentration of 10 mg/ml cis-platin) is also documented.
25 This novel result established the rationale for reformulating existing drugs using heparin and related kits (as devices), which can be performed by hospital pharmacists on-site, just prior to drug administration. This new approach can allow localized tissue (lesional)
30 uptake of drugs controlled by nonembolizing carriers, as follows:

- 35 a) by intravenous administration to the lungs (high efficiency delivery) and systemic lesional sites (moderate efficiency delivery); or

- b) by selective arterial perfusion to liver, kidney, brain, pelvis, extremities and other body sites (high efficiency delivery).

5 The present application describes that secondary tissue percolation of these hydrophylic drug-carriers occurs in normal target tissues for heparin-coated microspheres (intersitium, lymphatic and epithelial). In the present application, additional examples are
10 presented, which establish the general principal that, unlike the situation for lipid microemulsions, liposomes and other hydrophobic carriers, the present hydrophylic spheres percolate extensively through the interstitium of a tumor and the lesional gel of a spontaneous pneumonitis,
15 to reach both the outer spreading rims and the inner necrotic cores of these lesions. This provides new rationale for improved lesional penetration, cellular (microbial) access and uptake of drug carriers, and their entrapped (controlled) drugs. It is envisioned as
20 allowing improved drug access to tumor cells and microorganisms lying in sequestered sites.

 The present invention further specifies, that extensive percolation of interstitial tissue and lesional
25 foci, can be achieved by pre-emulsifying hydrophobic drugs, such as amphotericin B, with a poloxamer (preferably, the pluronics, F108 or F68, but alternatively, the pluronics, F127 or L61, or the tetronic, 908), which itself, percolates poorly, followed
30 by microencapsulation of these controlled-release subparticles (nanoparticles or emulsions) in a larger, hydrophilic matrix carrier (e.g., of heparin) which itself, percolates extensively. Such formulations are novel and can be envisioned as artificial white cells.
35 The outer, macromatrix performs the functions of the whole white cell (namely, bioadhesion to endothelium/epithelium,

transport of the particles across their initial barriers and interstitial percolation); and the subparticles (internal nanoparticles, emulsions, or complexes) perform the function of the internal white-cell granules (namely, attachment to the final interstitial-matrix or cellular target and the controlled release of drug). These drug carriers are novel, because they represent multistage microparticles (complexes), with functionally-oriented surface coatings which govern both their initial (body) biodistributions and subsequent (local tissue) distributions. Their specification and testing establish a rationale for improving the biodistribution, localized uptake, tissue percolation, and cellular (or microbial) ACCESS and uptake of drugs (and diagnostics) which do not normally accomplish these multiple steps on their own.

The original application of this series (Serial No. 033,432) and the present application further provide the novel rationale for secondarily controlling the release (or bioavailability) of drugs (diagnostics) from internally entrapped subparticles (nanoparticles, complexes or emulsion) of depot, time-release drugs (e.g. amphotericin B-pluronic F68 and amphotericin B-cyclodextrin complexes, after these internally entrapped entities have been released (either rapidly or slowly) from the outer macromatrices of heparin and heparin-coated dextran. This is envisioned as allowing the additional flexibility of locking the internal microparticles into target tissues (cells) even if the outer matrix carrier subsequently redistributes from its initial target site.

Final drug uptake into rapidly growing or dividing cells is envisioned as being potentially augmented by formulating the internal (or external) drug particles with transferrin, ferritin, or anti-tumor antibodies (or antibody fragments) which themselves, may not percolate

well into the most rapidly growing subregions of solid tumors (infections or abscesses). The improved gel percolation afforded by the present microcarriers is envisioned as improving the penetration of tumor glyocalyx, bony subcomponents of sarcomas, polyglucose hydrogels synthesized as attachment polymers by staphylococci and other organisms which cause osteomyelitis, periodontitis, and other bacterial infections; the proteinaceous microthrombi produced during invasive aspergillosis of the lungs and brain; the cartilaginous and ossified components of proliferative pannus which form in acute arthritis, and the gel substances which accompany other disease processes. Finally, these technologies are also envisioned as addressing the in vitro applications of penetrating cell-surface (cuticular) carbohydrates present on human and animal eggs and sperm, and on bacteria and yeast.

The present invention describes new entrapments of substances such as:

- a) amphotericin B in lipid microemulsions coated with TDMAC heparin, which produces selective uptake in the lung following intravenous injection (and putatively in other organ/lesional sites, by the routes/methods specified above); and
- b) the biomodulatory protein, interleukin 2, in albumin microspheres, which are amenable to coating with standard heparin, TDMAC heparin or heparin fragments, related glycosaminoglycans and their derivatives.

This provides the new rationale for heparin-modification and localization of previously hydrophobic

carriers, such as microemulsions, liposomes, and microspheres of polylactic and polyglycolic acids. The present invention also envisions the selective localization of three new classes of biopharmaceuticals: recombinant proteins, peptides and DNA/RNA vectors (for reconstituting genetic disease). Finally, it envisions that this new drug carrier technology will be useful for site-specific transplantation of whole cell in vivo. Cell preparation for such targeting is envisioned as being performed using a bifunctional adhesive agent, one component of which (e.g., heparin, fibronectin, laminin, Fab fragments of monoclonal antibodies, etc.) binds noncycotoxically to the transplantable cells, and one component of which (potentially the same component) adheres multivalently to the target endothelium (epithelium). High-efficiency transplantation is envisioned as being achieved by introducing these cells by the direct vascular (or intracavitary) route leading to the target organ, tissue or cells.

20

The present invention envisions that the following diseases (and drugs) can potentially be treated (and localized) in an improved fashion by using the described technology: cancer (antitumor agents, biological response modifiers, particularly IL-2 and TNF, radiation sensitizers, perfluorinated hydrocarbons, and hyperthermia augmenting agents); prophylaxis against tumor and bacterial metastasis (depot heparin itself, the new anti-metastatic peptide, peptide-11, etc.); diffuse infections and abscesses (antibiotic, antifungal and antiviral agents); deep pulmonary infections and central nervous system infections in immunocompromized and tumor patients (aminoglycoside and cephalosporin antibiotics, amphotericin B and other antifungals, and antivirals); chronic infection/inflammation of the urinary bladder or other sites (depot formulations of heparin, dermatan

35

sulfate, or pentosanpolysulfates, gangliosides, haptens and peptide blockers, and their derivatives); multiple sclerosis; diabetic angiopathy, acute and chronic arthritis (copper chelating agents, such as penicillamine; 5 steroids and steroid analogues), infarcts of the heart, brain, bowel and limbs (anti-adhesive agents which block neutrophil and platelet attachment, and free radical scavengers); disseminated intravascular coagulation (inhibitors of platelet activating factor, platelet 10 adhesion and fibrin polymerization); atherosclerosis (depot heparin, and heparin plus antilipidemic agents, such as probucol); acute coronary or cerebral thrombosis (tissue plasminogen activator -- administered intravenously or by selective arterial perfusion); genetic 15 and degenerative diseases, particularly of the liver, pancreas and brain (appropriate degradative enzymes, pancreatic islet cells, pituitary and brain cells, and transfecting gene vectors); endometriosis (danazol, anti-inflammatory agents, and anti-vascular proliferative 20 agents); infertility (sperm adhesives for in vivo and in vitro fertilization; prevention of allograft rejection, particularly for kidney, liver, bone marrow and lungs (steroids, immunosuppressives, cyclosporin A and others, antilymphocyte antibodies); acute and chronic asthma 25 (depot antiasthmatic agents administered by inhalation); pulmonary emphysema, prophylaxis and treatment, and prevention of intercurrent lung damage from smoking (peptide and other blockers of neutrophil elastase, antiinflammatory agents, inhibitors of platelet activating 30 factor, free radical scavengers, and their derivatives -- administered by inhalation, orally, intravenously, or as additives to cigarettes, cigars or pipe tobacco).

The bioadhesion carriers set forth in the present 35 application are envisioned as being preferred for the delivery of drugs which are highly toxic (certain

antitumor drugs, antifungal agents, antibiotics, and many
antivirals); drugs which are highly labile (peptides,
hormones, recombinant protein biomodulators, and their
analogues); agents which experience inappropriate
5 biodistribution or poor tissue access due to their large
molecular size or the presence of disseminated, competing
receptors in the body (lymphokines, cytokines, interferons
and other biologic response modifiers, and gene vectors);
anti-adhesion pharmaceuticals (as depot formulations, for
10 the prevention of cancer-cell metastasis, prophylaxis of
atherosclerosis, and inhibition of white-cell and platelet
adhesion to vascular endothelium); and most of the new,
recombinant biopharmaceuticals, whose production costs may
be extremely high, precluding administration in a freely
15 circulating form (all of the new recombinant proteins,
peptides and gene vectors, except in general, those which
act directly on bone marrow).

Additionally, these new formulations and processes of
20 facilitating cellular bioadhesion-uptake are applicable to
cellular microinjections in vitro, including those of
sperm, eggs, bacteria, yeast and others. Envisioned
agents include high-efficiency injections of drugs,
peptides, proteins, metals, diagnostic probes,
25 transfecting gene vectors, mutational probes, whole sperm,
sperm selected for sex preference by albumin gradient
centrifugation, and other agents which need to be injected
(ideally) under nonfusigenic conditions (e.g., conditions
which avoid fusigenic viruses or chemicals, such as
30 polyethylene glycol). This technology is envisioned as
having implications for the fields of in vitro
fertilization in both humans and animals, and for
recombinant-gene transfections.

35 The following examples illustrate the invention
described above.

EXAMPLE 1

Preparation of Acetone-Stabilized
and Heat-Stabilized heparin Micro-
spheres and Molecular Microaggregates

5
10
15
20
25
30
35

Beef lung heparin 100-200mg (152 units/mg, Upjohn Co.) was dissolved in 0.3-0.4 cc of distilled water and the solution emulsified in 6 cc of cottonseed oil (Sargent Welch, SC-11612) by vigorous vortex mixing for 1 to 5 minutes. This initial emulsion was added dropwise into 19 cc of stirred cottonseed oil which had been preheated to 114-122°C. This suspension was maintained at high temperature for 10 minutes and then allowed to cool to room temperature with continued stirring. (Alternatively, the heparin suspension was added dropwise into an identical volume of stirred cottonseed oil at 22°C. The oil suspensions were added dropwise into 30 cc (5 times the oil volume) of a mixture of 0.1% Tween 80 (Sigma Chemical Co.) in acetone in order to extract the oil phase (and to produce stable crystallization of the heparin in the unheated preparation). The microsphere-acetone suspensions were centrifuged at 1,250 x g for 5 minutes to sediment the spheres. The microspheres were extracted an additional 3 times with 0.1% Tween 80 in acetone (25 cc total volume or 4 times the oil volume). The resulting microspheres were either lyophilized to dryness or mixed thoroughly with 2% (w/v) Tween 80 in 0.5 cc of acetone and allowed to air dry for 24 hours at 22°C. Both procedures gave heparin microspheres which were stable upon suspension in water or isotonic saline and had an average particle diameter of between 7 and 50 micrometers (um) as measured by light microscopy. The sizes depended on the duration of vortex mixing in the oil emulsification steps above.

Heparin microaggregates averaging 0.1 to 0.2 um in size were produced as described in the preceding steps, but with the addition of by sonicating the initial 6 cc of oil emulsion for 5 minutes at 20,000Hz with a standard ultrasonifier and special microtip (Heat Systems, Inc.).

EXAMPLE 2

10 Preparation of Heparin Microspheres Containing Entrapped Amphotericin B

a. Entrapment of amphotericin-cyclodextrin complex.

15 Amphotericin B, 20 mg without deoxycholate (E.R. Squibb and Sons, Inc.) and gamma cyclodextrin, 31 mg (Polysciences, Inc.) were dissolved at a 1:1 molar ratio in 0.4 cc of dimethyl sulfoxide (Sigma Chemical Co.). Beef lung heparin, 49 mg (as in Example 1) was dissolved
20 in 0.8 cc of distilled water. The two solutions were mixed and then rapidly emulsified in 6 cc of cottonseed oil by vigorous and continuous vortex mixing. Aliquots were removed quickly (due to partial but controllable phase separation of the drug-cyclodextrin complex) and
25 added dropwise to 0.1% Tween 80 in acetone according to the exact procedures described for the nonheated microsphere preparation of Example 1. The percentage of starting drug entrapped was 70% and the final drug content in spheres was 14% (w/w). Resuspension in water and
30 isotonic saline resulted in two size populations of particles, the major fraction (ca. 85% by mass) comprised larger microspheres, 7 to 25 um in diameter, and the smaller fraction (ca. 15% by mass) comprised smaller microspheres, 0.3 to 1.0 um in diameter. These two
35 fractions were rapidly separable by micropore filtration. The larger spheres were observed microscopically to be

packed with yellow-colored refractile granules which were similar in size to the smaller particles just described. Water suspensions of the lyophilized spheres (combined size fractions) were amenable to complete sedimentation by centrifugation. By colorometric assessment of the fraction of amphotericin B (yellow color) which sedimented with particles at incremental times after aqueous resuspension, the $t_{1/2}$ of controlled release for amphotericin B was approximately 3 days.

10

b. Entrapment of amphotericin B pre-emulsified with pluronic F68 block copolymer.

Native amphotericin B, 100 mg without deoxycholate (E.R. Squibb and Sons, Inc.) and 12 mg of the pluronic F68 block copolymer (polyoxypropylene-polyoxyethylene, Green Cross Corp.) were suspended in 1 cc of distilled water and ultrasonified for 1 minute (as in Example 1) to produce an initial emulsion with a particle size ranging from 0.1 to 5 μm in diameter. This suspension was stirred overnight at 22°C in the dark, and then ultrasonified for an additional 1 minute. The resulting emulsion was significantly smaller, with a particle size ranging from 0.1 to 0.8 μm in diameter. This emulsion was centrifuged at 500 x g for 2 minutes in order to sediment the larger (potentially uncoated) drug particles. The supernatant (fine emulsion, ca. 30-50% of the mass) was removed and used for subsequent entrapment in heparin microspheres. This was done by adding 70 mg of beef lung heparin (Upjohn Co., as in Example 1) to the 0.9 cc of recoverable supernatant (fine emulsion) stirring for 5 minutes to obtain complete solvation of the heparin, adding the resulting mixture to oil (preferably at room temperature, alternatively at 114-125°C for 10 minutes, for extra stabilization), emulsifying it by vortexing, quickly stabilizing the emulsion by stirring into 0.1% Tween 80 in

acetone at 22°C, and processing as described in Example 1. The resulting microspheres had an average diameter of 3-15 um depending on the duration of vortex mixing. As assessed colorimetrically, the percentage of drug entrapped was greater than 70% and the final drug content was 20-30% (w/w).

Parallel microspheres were made as described above, except with dextran T70 (Pharmacia Fine Chemicals) as the major matrix component and heparin as the surface coating (10% by weight). For these spheres, the surface coating was added as described in Example 3 below (starting at the text position marked "SURFACE COATING."

15

EXAMPLE 3

Preparation of Dextran T70 Microspheres with a Heparin Surface Coating of 10% by Weight

20

Amphotericin B, 20 mg without deoxycholate (E.R. Squibb and Sons, Inc.) and gamma cyclodextrin, 30 mg were dissolved in 0.4 cc of dimethyl sulfoxide (Sigma Chemical Co.). Dextran T70 (Pharmacia Fine Chemicals), 49 mg was dissolved separately in 0.175 cc of dimethyl sulfoxide. The two aqueous suspensions were mixed and quickly emulsified in 7 cc of cottonseed oil (Sargent Welch, SC-11612). This oil suspension was added rapidly but dropwise to 0.1% Tween 80 in acetone (T-Ac), 35 cc. Microspheres were sedimented at 1250 x g for 5 minutes. The pellet was extracted one additional time with 10 cc of 0.1% T-Ac, resuspended in 0.5 cc of 2% T-Ac and allowed to dry for 45-60 minutes at 22°C (until the acetone odor was no longer detectible). A SURFACE COATING was prepared as follows: Beef lung heparin (Upjohn Co., as above), 10 mg predissolved in 0.5 cc of distilled water, was added to

35

the dried spheres. To this was added 6 cc of cottonseed oil (12 times the volume of water), and the suspension was emulsified by moderate vortex mixing, in order to apply the heparin coating to the surfaces of the previously

5 crystallized dextran spheres. This emulsion was once again stabilized by dropwise addition to 30 cc of stirred 0.1% T-Ac, and the microspheres sedimented at 1250 x g for 5 minutes. Three additional extractions were performed with 10, 9, and 6 cc, respectively, of T-Ac. The pellet

10 was resuspended in 0.5 cc of 2% T-Ac and allowed to air dry for 16 hours at 22°C. The percentage of drug entrapped was 65% and the final drug content was 12% by weight. Microsphere sizes ranged from 0.5 um to 30 um, depending on the duration of vortex mixing.

15

EXAMPLE 4

20 In Vitro Modification of Ulex Europaeus I Lectin Bound to Agarose Spheres

Ulex Europaeus I Lectin with affinity to endothelial factor VIII antigen, was obtained commercially (Vector Laboratories, Burlingame, CA) as a gel suspension in which

25 the Ulex lectin was bound by a stable ether linkage, to agarose spheres (25-75 um in diameter) of the lightly cross-linked polysaccharide comprising galactose plus 3,6-anhydrogalactose monomers). As obtained, the binding capacity was 2.5 mg of fucosyl glycoprotein per cc of gel

30 and the suspension contained 10 mM fucose, the sugar hapten of highest specificity to saturate all Ulex binding sites.

a. Preparation for injection of spheres with

35 hapten-blocked (fucose-bound) binding sites.

To 0.25 cc of the unwashed gel was added 0.75 cc of 0.2M phosphate-buffered 0.15N saline (Grand Island Biological Co.), in order to obtain a gel suspension which was sufficiently dilute for direct intravenous injection
5 (below).

b. Preparation for injection of spheres with unblocked (available) binding sites.

10 The gel, 0.25 cc was washed 3 times by centrifugation at 2500 x g with 0.8 cc each of 0.02 M phosphate-buffered 0.15N saline, in order to remove almost all of the fucose sugar hapten which was initially bound to the Ulex binding lectin. The resulting pellet of spheres was suspended in
15 a total volume of 0.8 cc for subsequent intravenous injection (below).

EXAMPLE 5

20

In Vivo Injection of Heparin Microspheres and Microaggregates Prepared as in Example 1

For all in vivo tests (this Example and Example 6
25 below), microspheres were suspended in phosphate-buffered saline (per Example 4) at a density such that their packed (centrifuged) volumes were 20 percent of their final volumes in suspension (spheres plus solution). Equivalent doses were given to each animal by injecting 0.125 cc of
30 the fully suspended material. Lung targeting was accomplished by intravenous injection into CBA mice, and brain targeting was performed by carotid arterial injection into Sprague-Dawley rats. Analysis of organ targeting, envelopment and extravascular migration of
35 spheres were carried out by 1) sacrificing representative test animals at 2, 5, 10, 15 and 20 minutes postinjection; fixing the brain tissue in 10% buffered formalin or

inflating their lungs to a fixed size by injecting 10% Carson's buffered (pH 7.4) formalin intratracheally at a pressure equivalent to a 20-cm column of water; 2) processing the fixed tissue sections for light and
5 electron microscopy; 3) staining these sections with hematoxylin and eosin (H & E), periodic acid Schiff (PAS), and reticulin histochemical stains; cutting (with a microtome) the light microscopic sections (below) at a 4-
10 um thickness; and 5) analyzing morphometrically, the processed sections for the number and microscopic position of spheres in relation to vessels, perivascular structures, interstitium and airspaces of lung, and the microvessels pericyte (astrocyte) processes (which abut the microvessels of brain), and brain tissue proper.

15

The legend for all Figures of tissue sections shown herein are: M = microsphere; V = microvessel; A = airspace; e = endothelial membrane; and n = endothelial nucleus.

20

a. Injection of heparin microspheres (0.125 cc) intravenously and localization in CBA mouse lung.

Figure 1 is a lung tissue section stained with PAS,
25 which is representative of the test mice sacrificed 2-5 minutes after intravenous injection of the unheated, acetone-stabilized heparin microspheres of Example 1. At the center is a typical heparin microsphere (M) approximately 20 um in diameter, which has become lodged
30 within the microvascular lumen of a lung capillary and is already completely enveloped by endothelial cell membrane (e), whose two nuclei (n) are present immediately adjacent and overlying the sphere. At the upper right-hand corner is an endothelial-coated microsphere (M) which has
35 migrated partially out of its lung capillary (V) and is beginning to lose its endothelial coating (e, at 4-6

o'clock on the sphere) at position 8-9 o'clock on the sphere.

Figure 2 is a lung tissue section stained with PAS, which is representative of the test mice sacrificed 10 minutes after intravenous injection of the same heparin microspheres as in Figure 1. At center is microsphere (M) the same heparin microspheres as in Figure 1. At center is microsphere (M) which has migrated almost completely out of its lung capillary (V) into the adjacent airspace (A). Endothelial membrane (e) and nuclei (n) are still present on the microsphere surface. There is minimal to no toxicity to the microvessel as evidenced by an absence of co-extravasted red blood cells or serum proteins (which would stain intensely with PAS). A second endothelial-coated and partially extravascular microsphere is present at lower right.

Smaller (nonembolizing) microspheres and microaggregates of all the heparin and heparin-coated formulations of Example 1 are observed to undergo similar envelopment and extravascular migration at approximately the same kinetics.

Table 1 summarizes the percentages and positions of intrapulmonary microspheres of 4 to 15-um diameters 15-20 minutes after intravenous injection:

Table 1

5	<u>Type of sphere</u>	<u>Approximate percentage of injected dose identified in lung</u>	<u>Percentage of spheres in extravascular locations</u>
10	1. Heparin (acetone)	35	85
15	2. Heparin (heated)	40	80
20	3. Plain agarose*	10	20

*Many of the remanent intravascular spheres were undergoing degradation due to serum amylase digestion, and only small fragments of these spheres could be identified.

20

These histologic and morphometric results document that the heparin microsphere surfaces induce rapid (less than 2 minutes) partial and/or complete endothelial coating which resulted in endothelial envelopment (walling-off) of the spheres, thereby functionally removing them from the vascular compartment (even during before they emigrate out of the vascular space). This slows intravascular degradation of the spheres and accelerates extravascular migration of the intact spheres (largely complete within 15 to 20 minutes), and greatly increases the proportion of spheres which become localized in the tissue (interstitial) compartment and airways

Larger heparin microspheres (25-75 um diameters) experience pulmonary captures and extravascular migrations similar to those of the Ulex I spheres shown in Table 2 of Example 6, below.

b. Injection of heparin microspheres into the carotid artery and localization in Sprague-Dawley rat brain.

Heparin microspheres from Example 1 (0.250 cc, 5-15 um in diameter) were injected into the carotid artery and the rats sacrificed at 15 minutes. One to seven, small (0.2-3.0) PAS-positive particles were observed in and
5 surrounding the microvessels of the cerebral and cerebellar cortex and the deep nuclei of the brain. Approximately 50% of the vessels were positive for emigrating particles. At 15 minutes postinjection, these particles were present largely along the processes of
10 pericytes lying adjacent to the brain arterioles and capillaries. (Pericytes are thought to be involved in the transport of nutrients from the vessels into brain parenchyma.) Smaller numbers of PAS-positive particles were identified at greater distances away from pericytes
15 within the extracellular compartment of brain tissue proper. Morphometrically, at least 15 percent of the injected microspheres were localized in brain tissue at 15 minutes.

20

EXAMPLE 6

In Vivo Injection of Ulex Europaeus I
Lectin Microspheres Prepared in Example 1

25

Ulex Europaeus I lectin microspheres (0.125 cc) were injected intravenously for localization in CBA mouse lung.

Figure 3 is a lung tissue section stained with PAS,
30 which is representative of the test mice sacrificed 2-5 minutes after intravenous injection of the fucose-blocked, Ulex Europaeus agglutinin I-coated spheres of Example 4. A larger microsphere (M) is present (at left center) in the vascular space (V), which has undergone almost
35 complete envelopment by endothelial membranes (e) and nuclei (n). A smaller microsphere (M) is present (at right center) which has undergone both endothelial

envelopment and almost complete extravascular migration into the airspace (A). However, it remains attached to the basement membrane of the small vessel from which it emigrated. Remnants of endothelial membrane (e) still
5 coat it at the surface of attachment but have been lost from the free surface. Histologic comparisons of heparin and Ulex I microspheres have revealed that a higher proportion of emigrated Ulex I spheres remain attached to the abluminal basement membrane, whereas a higher
10 proportion of the heparin spheres (Example 5 above) have further migrated into distant structures, including lymphatics and airways. For all spheres, there was an absence of red blood cell attachment on the downstream surface, indicating that any tendency towards binding or
15 agglutination of red cell surface blood-group substances had been successfully blocked by the sugar hapten. Also, there was histologic evidence for the induction of acute coagulopathies or endothelial toxicity.

20 Figure 4 is a lung tissue section stained with a reticulin stain, which is representative of the test mice sacrificed at 10 minutes after intravenous injection of the identical fucose-blocked, Ulex Europaeus agglutinin-coated spheres of Example 3. At center, is a microsphere
25 (M) which has undergone complete emigration from the vascular space (V) into the airspace (A), with continued attachment to the abluminal basement membrane. This sphere shows remanent coating by endothelial membranes (e,e) but uncoating on the opposite surface (u). Small
30 fragments of reticulin (a connective tissue component of the vessel wall) have been carried through into the airspace with the microsphere (dark stringy material just below "A") but no red blood cells have been released from the vessels into the airspace. (Emigration of reticulin
35 is not observed with emigration of the smallest, 10-um spheres present in this Ulex I suspension.) The

microsphere of Figure 4 is beginning to undergo degradation in the airspace at 10 minutes. At 20 minutes, the extent of degradation is only slightly greater than at 10 minutes for most of the extravasated sphere matrices (not shown). Examples 3 and 4 indicate that fucose-blocked Ulex I spheres undergo efficient uncoating upon contact with endothelial surfaces which have binding sites for the Ulex I lectin, and that this event induces endothelial envelopment and rapid extravascular migration of the spheres. Similar responses are seen for unblocked microspheres (with exposed Ulex I binding sites.) For smaller (nonembolizing) Ulex I spheres of 3-5 μm diameters, such uncoating would be expected to occur preferentially in the microvessels supplying focal lesional tissues (involved by inflammation, infection and tumor).

Figure 5 is a lung tissue section stained with PAS, which is representative of the test mice sacrificed 20 minutes after intravenous injection of the identical fucose-blocked spheres of Examples 3 and 4. This exemplifies the rare intravascular microsphere (M) which can still be identified at 20 minutes. Although it has undergone nearly complete endothelial envelopment and partial extravascular migration, its migration is not yet complete. This rare example shows that the portion of the sphere which is most completely coated by endothelial membranes (e) is the most protected from intravascular amylase digestion and remains morphologically intact. Conversely, the portion of the sphere which is uncoated (the portion which invaginates most deeply into the vascular compartment "V") has undergone morphologic fragmentation (f) and will shortly become completely digested within the vessel unless it first completes the process of emigration. This indicates that endothelial envelopment indeed renders the emigrating particles

extravascular and hence protects them from digestion during the process of emigration. By the same process of walling off the particle, it can be inferred that most of the drug which is released in this newly formed
5 endothelial pocket during microsphere emigration would also be walled off and released into the tissue compartment as the particle emerges on the tissue side. Note that blood flow has already been re-established in this vessel at positions 5-7 o'clock around this sphere.
10

Figure 6 is a representative example of control microsphere (M_C) of plain agarose which is present within a lung microvessel (V) 10 minutes after intravenous injection. In contrast to the Ulex I (and heparin)
15 spheres, this sphere shows no evidence of endothelial coating on either the upstream or downstream free surfaces (u, uncoated). It also shows no evidence of beginning extravascular migration. A reticulin stain (not shown) indicates intact reticulin around all aspects of the
20 vessel wall with which the sphere is in contact. Such control spheres (without Ulex I or heparin surfaces) migrate in a delayed (20 minutes or longer) inefficient manner (see Table 2 below), and undergo intravascular degradation with downstream release of microsphere
25 fragments and drug.

Table 2 summarizes the percentages and positions of intrapulmonary microspheres of 25 to 75-um diameters at 10-20 minutes after intravenous injection:
30

Table 2

5	<u>Type of sphere</u>	<u>Approximate percentage of injected dose identified in lung</u>	<u>Percentage of spheres in extravascular locations</u>
10	1. Ulex I, fucose-blocked*	90	80
10	2. Ulex I, unblocked*	90	90
15	3. Plain agarose **	10	20

20

25

*The higher lung-capture percentage of Ulex I versus the heparin spheres of Example 5, Table 1, is due to the larger diameters of these particles. Note, however, that plain agarose particles of the larger diameter (Table 2) are not effectively transported into the tissues, and hence, their capture percentage at 10-20 minutes is also low due to intravascular degradation and release from the lung. Smaller spheres with Ulex I surfaces would be expected to undergo capture percentages equivalent to heparin spheres of the same size.

30

**Many of the remanent intravascular spheres were undergoing degradation due to serum amylase digestion, and only small fragments of these spheres could be identified.

EXAMPLE 7

35

Prophetic Formulations of Preferred and Alternative Embodiments.

40

The following embodiments continue and augment those presented heretofore and include

1. Microparticles expanded to include nanoparticles and molecular complexes of diameters and Stokes radii down to 0.02 nanometers.

45

2. Additional matrix materials envisioned as follows:

- 5 a) preferably, Type IV collagen or albumins, coated with multivalent heparins or TDMAC heparin, respectively;
- 10 b) alternatively, lisinopril-albumin conjugates, polylactic acids, polyglycolic acids, mixtures of polylactic and polyglycolic acids in crystalline and/or amorphous forms, starch, hydroxyethyl starch, and other starch derivatives, oil-in-water emulsions, liposomes, laminin (and its fragments), type I collagen
- 15 (and its subunits), fibronectin (and its fragments), antithrombin III (and its binding subunits);
- 20 c) For paired-ion complexation and stabilization of negatively charged matrix materials:
- (1) preferably, protamine or polyethyleneimine (PEI);
- 25 (2) alternatively, poly-L-lysine, or other positively charged amino acids or intermediate metabolites, bacterial or recombinant products, or their derivatives, for which, in order to minimize in vivo
- 30 (particularly endothelial) toxicity, the positively charged moieties are located predominantly internally and the negatively charged moieties are located predominantly on the external surfaces;

d) For semiselective tumor-cell uptake, inclusion of negatively charged or neutral polycarbohydrates;

5 (1) preferably, the sulfated polyglucose, heparin, or neutral polyglucose, dextran, as specified initially in the parent document (Serial No. 033,432);

10 (2) alternatively, dermatan sulfate, pentosanpolysulfate or starch, and their derivatives.

3. Additional surface coatings and drug complexing
15 substances are specified as follows:

a) preferably, low-molecular-weight fragments of dermatan sulfates;

20 b) alternatively, lisinopril; lisinopril conjugates of dextran, starch, starch derivatives or albumin; negatively charged glycolipids or gangliosides and their derivatives, TDMAC
25 heparin (or other hydrophobically modified heparins or glycosaminoglycans, GAG's) in which the hydrophobic substituent is attached to the heparin (or GAG) by either covalent conjugation or paired-ion complexation (particularly for use
30 in coating matrices which are hydrophobic or have hydrophobic subregions, such as denatured albumins, polylactic and polyglycolic acids, oil-in-water emulsions, and liposomes);

35 c) For targeting cellular and/or matrix heparin sulfates or heparin glycosaminoglycans in vivo;

- (1) preferably, type IV collagen;
- (2) alternatively, antithrombin III,
recombinant heparin cofactor II, 33,000
dalton proteolytic fragment of fibronectin,
and laminin;
- 5
- d) For targeting tissue matrix components exposed
by disease processes in vivo:
- 10
- (1) preferably, type IV collagen;
- (2) alternatively, laminin, antithrombin III,
recombinant heparin cofactor II,
fibronectin-binding polypeptide, Fab
fragments of AHB-2 monoclonal antibody
(directed against the 33,000 dalton
proteolytic fragment of fibronectin)
fibronectin, 33,000 dalton proteolytic
fragment of fibronectin;
- 15
- 20
- e) For targeting renal glomeruli and the kidneys:
- (1) preferably, the FDA-approved intravenous
injectable, protamine;
- 25
- (2) alternatively, polyethyleneimine, poly-L-
lysine or other positively charged amino
acids or intermediary metabolites,
bacterial or yeast-derived recombinant
products, NH₂-containing monomers,
oligomers or polymers, or derivatives of
the preceding compounds.
- 30

f) For augmentation of gastrointestinal uptake:

(1) preferably, sodium lauryl sulfate or dioctyl sodium sulfosuccinate;

5

(2) alternatively, the alkyl aryl sulfate, G-3300, sodium taurocholate, or other biocompatible, conjugated, complexed, physically mixed or emulsified, sulfated and sulfonated detergents.

10

g) For augmented binding to sites of intravascular coagulation/fibrinolysis:

(1) preferably fibrinogen;

15

(2) alternatively, Fab fragments of anti-fibrinogen antibodies, and reagents which bind to the activated surface coagulation factors, IIa, Va, VIIIa, IXa, XIa, endothelial surface phospholipids, vWF, etc.

20

Any or all of the preceding surface coatings are envisioned as being applied to their underlying matrices either as a thick or thin (monomolecular) film, and in a single-fluid phase, fluid-emulsion, or by microparticulate suspension methods, which include air suspension, ultrasonic suspension in vacuum, and which are accomplished by one or more of the following physical or chemical means;

30

- a. hot-plasma coating;
- b. cold-plasma coating;
- 5 c. vacuum sputtering;
- d. fluid-phase transfer (direct deposition or reverse emulsification);
- 10 e. particle-surface activation by tresyl chloride, cyanogen bromide or alternative chemical reagents, followed by covalent bonding of receptor-binding peptides or proteins;
- 15 f. particle-surface activation by periodate oxidation of vicinal hydroxyl groups, followed by covalent bonding, by aldol condensation, of carbohydrates, dextrans, glycoproteins, or glycolipids; or, by amino condensation, of
20 proteins and peptides, with subsequent reduction with borohydrides;
- g. bonding of internal and external particles (or emulsions, particle-emulsion hybrids, or
25 glycosaminoglycan-detergent complexes or covalent conjugates) by any of the previous methods;
- h. for the cases in which either the particulate
30 matrices or pharmaceutical-complexing materials (e.g., type IV collagen, laminin, antithrombin III, and fibronectin--for heparin; and/or other glycosaminoglycans, peptides, proteins, etc.),
35 have native binding sites for the surface coating materials, direct addition of the preformed particles (or complexes) to the

5 complementary surface material, such that the
surface coating (complexing substance) binds the
matrix by noncovalent association, and leaves
additional (identical or alternative) free
10 binding groups (preferably of heparin or type IV
collagen; alternatively of laminin, dermatan
sulfate, or other glycosaminoglycans) available
on the external surfaces for endothelial or
epithelial adhesion); also, in cases where such
15 matrix-binding materials are not natively
multivalent, a procedure for polymerizing or
complexing the haptenic subunits together, such
that they are reformulated to become
multivalent, and such that these synthetic
20 multimers can bind both internally, to the
underlying matrix, and externally, to their
biological targets: endothelium, epithelium
and/or extracellular matrix components.

20 4. The present invention envisions formulations
which employ additional detergents as excipients for
preparing the internal drug nanoparticles, nanoemulsions,
or other internally entrapped, controlled-release
subcapsules, complexes or agents (as was described
25 initially in the parent document (Serial No. 033,432) for
formulation and entrapment of the internal drug emulsion,
amphotericin B-pluronic F68. Such detergents include:

- 30 a) preferably, sodium deoxycholate;
- b) alternatively, cholesterol, Tween 80,
zwitterionic detergents, or other biocompatible
nonionic, polysulfated or positively charged
35 detergents, as needed to formulate stable drug
emulsions.

5. The present invention envisions the use of additional methods for matrix stabilizing and controlling the release of drugs. These include:

- 5 a) preferably, for proteins and heat-labile peptides, chemical cross-linking with fresh formaldehyde or paraformaldehyde;
- 10 b) alternatively; addition of thickening agents, such as polylactic and polyglycolic acids, polyaminoacids, poly-L-lysine, polyethyleneimine, glycerol, polyglycerols or polyalchols (with or without heating or chemical reaction), polyethylene oxides, biodegradable
- 15 poloxamers or poloxamines (pluronic or tetronics), poly-COOH compounds (polycarbols), or polyamines.

6. Additional methods of microparticle formulation are envisioned as including (particularly for the purposes of product scale-up):

- 25 a) preferably, extrusion of matrix (and/or surface) components through single (and/or coaxial), sonified or air-stream-fractured micro-orifices (single or multiport);
- b) alternatively, aerosolization using hybrid, homogenization-spray drying apparatus.

30 7. The present invention envisions additional methods of extracting the solvents used for phase emulsification and simultaneously crystallizing the matrices, surfaces and/or entrapment materials):

- a) preferably, hexanes;
- b) alternatively, ethanol or methanol.
- 5 8. Additional methods of sterilization (and/or particle sizing) of the final (or subfinal) preparations, include:
- a) preferably, for heat-stabile agents:
10 autoclaving at 120°C for 10-20 minutes;
- b) preferably, for heat-labile agents:
- (1) submicron filtration of complexes and
15 nanoparticles; and
- (2) irradiation of particles larger than 0.22
um;
- 20 c) alternatively, ultrasonification.

EXAMPLE 8

25 Formulation of controlled-release, heparin-amphotericin B-pluronic-F108 drug particles

Two formulations of heat-stabilized, heparin-amphotericin B microspheres were prepared as described in
30 Example 2.b. with the following modifications: for pre-emulsification of amphotericin B (E.R. Squibb and Sons, Inc., Princeton, NJ), the pluronic detergent, F108 (BASF Corp., Parsippany, NJ) was substituted for pluronic F68; heat stabilization of the drug matrix was carried out at
35 115°C for 10 minutes with continuous shearing using a high-speed sonicating probe-homogenizer (Brinkmann

Instruments, Westbury, NY); and two fractions of spheres with different diameters were harvested by centrifugation of the larger ones at 250 x g for 15 seconds, in acetone + 0.1% (w/v) Tween 80, followed by complete sedimentation of the smaller ones which initially remained suspended. This produced two size fractions of amphotericin-B entrapment spheres, each of which comprised 50% of the total product weight.

10 a) The smaller fraction comprised nanospheres, which ranged from 150-700 nanometers (nm) in diameter. This nanosphere formulation contained 33.6% (w/w) amphotericin B, as determined by extraction in dimethylsulfoxide:methanol (10:90) and reverse-phase (C18) high performance liquid chromatographic (HPLC) analysis of
15 extracted amphotericin B. Upon aqueous suspension of the nanospheres in intravenous injection solution, 5.3% of the total drug (= the surface fraction) was released rapidly (over 15 minutes). The remaining drug, 94.7%, was
20 released in a controlled fashion, with a t_{1/2} of 24 hours.

 b) The larger fraction comprised microspheres, which ranged from 1-8 micrometers (um) in diameter. This microsphere formulation contained 41.7% amphotericin B
25 (w/w), 2.7% of which was released rapidly, and 97.3% of which was released in a controlled fashion, with a t_{1/2} of 32 hours.

EXAMPLE 9

5 Testing the pulmonary and extrapulmonary
 localization of intravenously administered
 heparin-amphotericin B-F108 nanosphere and
 microsphere formulations prepared as in Example 8

 Organ localization of the amphotericin B formulations
 prepared as in Example 8, was tested by intravenous
10 injection into adult male CBA/J mice. Drug concentrations
 were analyzed both chemically and histologically.
 Chemical analyses were performed by sacrificing the
 animals at 10 min to 6 hrs postinjection and performing
 tissue homogenization, drug extraction, and HPLC
15 quantification of drug (as described for the microspheres,
 in Example 8, above). Histological analyses of
 amphotericin-polymer localization and tissue-subregion
 distribution were performed by sacrificing the animals at
 15 minutes postinjection, and performing a special
20 histochemical stain (extended oil red O) on the 10-micron
 thick sections, representative of all major body organs.

 Histologic results revealed that carrier localization
 and uptake by endothelium at all anatomic sites, was
25 nearly complete within 10 min and entirely complete at 15
 min postinjection. By HPLC analysis, blood levels were at
 the limits of detection at 10 minutes and undetectible at
 1 hour postinjection. Hence, the 1-hour chemical data
 (below) represent equilibrated biodistributions. The 1-
30 hour results for both the nonembolizing nanospheres and
 marginally embolizing microspheres of Example 8, were
 compared with those of standard amphotericin B (Fungizone
 formulated as a simple amphotericin B-deoxycholate
 nanoemulsion (E.R. Squibb and Sons, Inc., Princeton, NJ).
35 All doses of amphotericin B were maintained at 0.75 mg/kg
 of body weight.

(1) Biodistribution of nanoparticulate heparin-amphotericin B-F108 at 1 hour postinjection:

(a) Total body drug recovered 70%;

5

(b) Organ concentrations (ug amphotericin/gram tissue, wet weight): lungs 15, liver 8.3, kidneys 1.1, spleen 6.2, brain 0.20, heart 1.4;

10

(c) Percentage of injected dose localized per gram of tissue (wet weight): lungs 52, liver 29, kidneys 3.8, spleen 21, brain 0.7, heart 4.8.

15

(2) Biodistribution of microparticulate heparin-amphotericin B-F108 at 1 hour postinjection:

(a) Total body drug recovered 55%;

20

(b) Organ concentrations (ug amphotericin/gram tissue, wet weight): lungs 25.7, liver 5.0, kidneys 0.4, spleen 2.2, heart 0.3, brain 0.2;

25

(c) Percentage of injected dose localized per gram of tissue (wet weight): lungs 94, liver 18, kidney 1.4, spleen 8.2, heart 0.4, brain 0.5

30

(3) Biodistribution of Fungizone (amphotericin B-deoxycholate nanoemulsion) at 1 hour postinjection:

- (a) Total body drug recovered 58%;
- (b) Organ concentrations (ug amphotericin/gram tissue, wet weight): lungs 4.0, liver 6.7, kidneys 2.5, spleen 11, heart 0.3, brain 0.
- (c) Percentage of injected dose localized per gram of tissue (wet weight): lungs 14, liver 24, kidneys 9.2, spleen 38.3, heart 1.3, brain 0.

These results establish that preferential and rapid lung uptake of intravenously administered amphotericin B occurs when it is formulated as heat-stabilized heparin-Fl08 spheres of either subembolizing or embolizing diameters. These results of drug localization correlate exactly with the morphometric results of carrier localization, which were earlier obtained. As presented in the present application, the chemical uptake and anatomic subregion locations of amphotericin B entrapped in subembolizing nanospheres, further establish that the mechanism of uptake is as follows: endothelial bioadhesion, plus induced active endothelial envelopment and transport of the heparin-coated particles into the tissue interstitium. Further evidence for initial endothelial bioadhesion is provided by the observation that the 1-hour lung uptake of heparin-amphotericin B nanoparticulates is decreased by 52% if soluble heparin is injected at the same time as heparin-drug particles. Further evidence that active endothelial transport of amphotericin B is induced by the heparin surface, is provided by the combined results that lung sequestration of drug is nearly complete and blood levels nearly zero at the very early time of ten minutes following intravenous injection. Such rapid and efficient uptake is not

observed for dextran and agarose placebo particles which lack the heparin surface coating.

The quantity of amphotericin B which becomes
5 deposited in the lung after one hour, also remains largely within that organ at extended times, as assessed both histologically and by delayed chemical analyses. By chemical analysis, the 6-hour retention of amphotericin B within the lungs of 6-month-old adult CBA/J mice was 60 to
10 70 percent of the 1-hour values. By histochemical staining, amphotericin B distributes widely within lung alveoli, pulmonary intersitium, respiratory epithelium, and bronchial/tracheal lymph nodes. This indicates that tissue percolation of the drug carrier is extensive, and
15 that such percolation can provides wide coverage of both the primary tissue targets and the secondary, lymphatic drainage routes. In the occasional mice which had acquired focal pneumonitis (spontaneous mycoplasma infections), the density of nanospheres and microspheres
20 was significantly higher in these foci of infection than in the surrounding normal tissues. This indicated that heparin nanospheres (and microspheres) have an additional advantage of secondary lesional accumulation (of amphotericin B). Hence, although extra-pulmonary
25 redistribution occurred, its extent was minor, and importantly, the intra-pulmonary redistribution which also occurred, favored the selective accumulation and prolonged retention of drug in sites of infection (vis a vis normal tissue components).

30

An intentional superdose of (subembolizing) heparin-amphotericin B-F-108 nanospheres was administered intravenously to a group of mice, in order to test the systemic organ uptake which occurred following
35 supersaturation of lung receptors. This resulted in secondary organ clearance by the liver, however, the

histologic pattern differed importantly from that usually observed with nonspecific (nonlocalizing) particulates in that these new heparin particles became localized within hepatocytes, as well as Kupffer cells. This established
5 that the heparin particles experienced general endothelial-cell uptake rather than preferential phagocytic-cell uptake. The heparin-amphotericin B-F108 nanospheres also continued to avoid the kidneys (major site of amphotericin toxicity). These results, together
10 with the previous results of brain uptake by selective carotid arterial perfusion (Example 5.b.), establish that it is also possible to achieve high-efficiency endothelial bioadhesion, selective drug uptake and retention at sites (organs) other than lung.

15

EXAMPLE 10

20 Formulation of a TDMAC heparin-coated lipid nanoemulsion containing amphotericin B

This nanoemulsion was produced by reformulating the FDA-approved lipid emulsion, 20% (w/v) Intralipid (KabiVitrum, Inc., Alameda, CA) by adding amphotericin B
25 at 15% (w/w) to the emulsion, allowing it to stir into the (soybean) oil component of the emulsion for 20 minutes, then adding TDMAC heparin (Polysciences, Inc., Warrington, PA) at 0.2% (w/w) to the resulting composite, and
30 sonicating this for 20 seconds, in order to accelerate the incorporation of TDMAC heparin into the egg-yolk phospholipid surface. The resulting composite lipid-emulsion particles ranged from 200 to 700 nanometers in diameter, and were stable (by inverted light-microscopic analysis) for longer than 2 hours (sufficient to permit
35 controlled intravenous infusion).

EXAMPLE 11

Testing the pulmonary and extrapulmonary localization
of intravenously administered TDMAC heparin-
5 amphotericin B-lipid nanoemulsion prepared in Example 10

The TDMAC heparin-lipid nanoemulsion of amphotericin
B (formulated as in Example 10) was injected intravenously
into adult male CBA/J mice. At 1 hour postinjection, the
10 lung-to-kidney ratio of amphotericin B content was
increased significantly to 1.44:1 (relative to that
observed for Fungizone, = 1.17:1). Also, drug
concentrations in the spleen, liver and kidney were
reduced by multiples of 2.2 and 1.6, and 1.7,
15 respectively, relative to those achieved by an equal dose
of Fungizone. This established the capacity of TDMAC
heparin-lipid microemulsions of amphotericin B, to
minimize the pronounced phagocytic uptake both by the
reticuloendothelial organs/cells, as well as the clearance
20 by kidneys (the organs of major toxicity).

Special histologic staining was performed on the
frozen sections of all organs at twelve minutes
postinjection. This confirmed moderate staining intensity
25 and homogeneous distribution in lung alveoli, of the TDMAC
heparin-lipid emulsion of amphotericin B. It further
indicated that significantly less of the Fungizone
emulsion became localized in the lung. These results
indicate that heparin modification of nanoemulsions
30 resulted in improved pulmonary localization of
amphotericin B. Although this localization was less
efficient than that afforded by stabilized nano- and
microcarriers, it was still significantly more efficient
than that afforded by a simple nanoemulsion (without
35 heparin).

EXAMPLE 12

Formulation of a heparin-cis-platin, paired-ion emulsion complex

5

The FDA-approved antitumor drug cisplatin (Platinol, cis-diaminodichloro platinum coordinate, Bristol Laboratories, Syracuse, NY) was reformulated as a metastable heparin complex, by rehydrating Platinol with distilled water at a concentration of 10 mg/ml, mixing the drug with beef lung heparin (Upjohn Co., Kalamazoo, MI) at weight ratios of 1:1.1 (cis-platin to heparin, w/w), and ultrasonifying for 1.5 min, in order to accelerate the formation of paired-ion complexes between the amino groups of cis-platin and the sulfate groups of heparin. This resulted in a heparin-coated cis-platin microemulsion complex, with particle dimensions of 0.2-1.5 um (cis-platin itself being insoluble at concentrations above ca. 2 mg/ml). The resulting microemulsion complex remained stable for longer than 1 hour at 22°C (sufficient for controlled intravascular infusion).

EXAMPLE 13

25

Testing the pulmonary and extrapulmonary localization of intravenously administered heparin-cis-platin, paired-ion emulsion complex prepared in Example 12

The heparin-cis-platin microemulsion complex prepared in Example 12, as well as native cis-platin (Platinol, dissolved at 1 mg/ml to produce complete solubility) were infused intravenously into different groups of adult male CBA/J mice. The mice were sacrificed at 15 minutes postinjection, and histologic sections of all organs were stained by an intensified Prussian blue iron reaction, which identified (semiquantitatively) all of the

intracellular platinum and most of the extracellular platinum present in target tissues, by staining it aquamarine blue. (This newly developed stain was initially tested on cis-platin in vitro, in order to document the specificity and color of platinum staining.) Results were as follows:

- 5
- 10
- 15
- 20
- 25
- 30
- 35
- (a) Mice receiving standard intravenous Platinol showed moderate-to-intense staining of the liver (centrilobular regions) and almost no staining of lungs.
 - (b) Mice receiving the reformulated heparin-cis-platin emulsion complex showed moderate-to-intense staining in the lungs, as follows: occasional endothelial staining; substantial staining of lung interstitium, alveolar pneumocytes, respiratory epithelium and bronchial and tracheal lymph nodes; and to a much lesser extent, alveolar macrophages. There was no evidence of pulmonary endothelial toxicity (which, if present, would have appeared as endothelial vesiculation, deposits of extravasated plasma protein, extravasated erythrocytes, and/or intravascular coagulation). Liver staining was approximately 1/10th as abundant as lung staining.

These results establish that high concentrations of Platinol (which are usually toxic to endothelium) can be successfully reformulated as a heparin microemulsion complex, and that the heparin component can induce endothelial binding and transcellular uptake of the complexes in a fashion that protects the endothelium from the toxic effects of the drug. These results further indicate that cis-platin (Platinol) need not be formally

microencapsulated in matrix or emulsion carriers, in order to undergo endothelial binding, uptake and preferential tissue access/localization. Rather, it is effective when reformulated on site using a reagent kit (device) comprising heparin.

EXAMPLE 14

10 Epithelial uptake of heparin-iron particles into the lungs following intratracheal administration

Heparin nanospheres, 200-800 nm in diameter, were prepared as in Example 8 (above), except that the metals, iron oxide (Fe_3O_4) and ionic iron (Fe^{+3}), were microencapsulated in place of amphotericin B, in order to allow subsequent histochemical identification of the entrapped materials in tissue sections, using the Prussian blue iron stain.

20

Nanospheres (0.5 cc of a 0.5 mg/ml suspension in 0.15M NaCl) were injected into the trachea of pentobarbital-anesthetized adult male CBA/J mice. The mice were sacrificed at 15 minutes postinjection, histologic sections of the lungs prepared, and the sections stained using the standard Prussian blue iron reaction, in order to identify the quantify and positions of microspheres and entrapped iron. The lungs stained positively for microsphere iron. Staining was present in a pattern and intensity identical to those observed following intravenous administration of the amphotericin-containing nanospheres (described in Examples 8 and 9, above). The staining of liver and kidneys was negligible to very low. This established that stabilized heparin nanocarriers (with heparin surfaces) were taken up into lung tissue by epithelial transport, that these carriers

deposited a pulmonary reservoir of the entrapped materials (iron compounds), and that a high proportion of the injected dose became localized in the lungs (relative to other organs) when administered via the airways.

5

EXAMPLE 15

10 Epithelial uptake of heparin nanocarriers into the bladder, small and large bowel (and the draining portal circulation) following intracavitary administration

Nanospheres prepared as in Example 14, were introduced by needle injection into isolated small and large bowel segments, or into the bladder of 15 pentobarbital-anesthetized adult male CBA/J mice. The mice were sacrificed 20 minutes after nanosphere administration, and the tissues prepared and stained as in Example 14. Moderate to marked staining was present in 20 the superficial and deep mucosal layers of both the small and large bowel. Occasional staining was identified in the portal (draining) capillaries and mesenteric lymphatics of the injected bowel segments, and in the deep capillaries of the bladder wall. These results indicated 25 that localized uptake of heparin-coated nanospheres across the bowel and bladder mucosa was achieved by the transepithelial routes. They finally indicated that a portion of the drug particulates taken up via the gastrointestinal tract, were made available for liver 30 and/or systemic distribution via the portal circulation; and that secondary drug targeting at systemic sites is possible following enteric administration of the particulate carriers formulated as in Examples 1-3 and 14.

35

EXAMPLE 16

5 Preferential accumulation of intravenously administered heparin-coated nanoparticles in the tumors of Buffalo rats bearing Morris 7777-strain hepatocellular carcinomas grown in the liver, lungs and subcutaneous sites

The heparin-iron particulates formulated as in
10 Example 14, were tested, as were heparin-coated, heat-stabilized nanoparticles (200-900 nm in diameter, prepared identically, except using albumin as a matrix; and using beef-lung heparin, Upjohn Co., Kalamazoo, MI, as a surface coating applied by fluid re-emulsification). These marker
15 particles were injected intravenously into pentobarbital-anesthetized Buffalo rats bearing 7777-strain Morris hepatocellular carcinomas of the liver or subcutaneous hind limb (primary sites) and the lung (metastatic site). Tumor accumulation and subregion distributions were
20 assessed histochemically (as in Example 14) at intervals of 20 min to 2.5 hrs postinjection. By morphometric analysis, early (20-min) and prolonged (2.5-hr) accumulation was observed in the tumor interstitium, within the tumor cells themselves, and in occasional host
25 macrophages. Such accumulation was observed regardless of the gross anatomic site of tumor. The ratios of stainable tracer metal present in tumor, versus adjacent and distant normal tissues, was between 4:1 and 10:1 (for tumor masses at all three body sites). Importantly, the staining
30 patterns also revealed widespread tumor percolation of the carriers, and further established the preferential accumulation of tracer iron in the following tumor subregions most relevant to drug therapy (diagnosis):

- 35 a) at the boundaries between tumor and adjacent normal tissues (i.e., the most actively growing subregions); and

- b) at the boundaries between viable and centrally necrotic (dead) tumor, plus the central necrotic regions themselves.

5 These results indicate that intravenous administration of the heparin-iron nanoparticles allows them to:

- 10 (1) distribute via the systemic vasculature,
- (2) become selectively localized in a representative malignant tumor,
- 15 (3) Percolate widely throughout the tumor interstitium,
- (4) become selectively concentrated in the therapeutically and diagnostically relevant subregions of tumor, and
- 20 (5) become taken up semiselectively by tumor cells (due to the accentuated cellular uptake of a sulfated polyglucose compound, e.g., heparin, by the induced anion-
- 25 transport channels of malignant versus normal hepatocyte.

EXAMPLE 17

30

Formulation of heparin-coatable albumin microspheres containing the microencapsulated biomodulator, recombinant human interleukin 2

35

The biological response modifier, recombinant human interleukin 2 (125-ala-modified IL-2, Amgen Corporation,

Thousand Oaks, CA), was microencapsulated in albumin microspheres and nanospheres (with diameters as described in Example 8, above) by emulsion-polymerization entrapment. In order to maximally preserve biological activity, the albumin-interleukin copolymeric matrix was stabilized by chemical cross-linking with fresh 0.5 to 7.0% formaldehyde (instead of heating), and the cross-linking reaction was quenched with excess glycine. Upon aqueous hydration, IL-2 was released from the spheres in a biologically active form, with a $t_{1/2}$ of 42 minutes (as assessed by the biological effects of release supernatants on the incorporation of tritiated thymidine by IL-2-dependent T-cell lines tested in vitro). This microsphere formulation of IL-2 was amenable to direct coating (of the preformed particles), both with TDMAC heparin (as described in Example 10, above), and standard heparins (beef-lung heparin, Upjohn Co., Kalamazoo, MI, as described in Example 2.b) and with porcine intestinal mucosal heparin, Sigma Chemicals, St. Louis, MO). These results establish that the biological response modifier, IL-2, which comprises a globular protein, can be entrapped in particulate carriers which become selectively localized in tumors and/or the lungs and brain (as described above).

CLAIMS:

1. A composition of matter comprising a carrier having a surface, at least two molecules of drug or diagnostic agent contained by the carrier and a multivalent binding agent specific for endothelial surface determinants, at least a portion of said binding agent being attached to the surface of said carrier.
- 10
2. The composition of matter of claim 1 wherein the carrier has a size of between about 1 nm and about 250 um.
- 15
3. The composition of matter of claim 1 wherein the binding agent is defined further as bioadhering to endothelial surface determinants and inducing envelopment of the carrier by endothelial cells of a vascular wall and transfer across said wall to proximal tissues.
- 20
4. The composition of matter of claim 1 wherein the carrier comprises one or more of macromolecules, microaggregates, microparticles, microspheres, nanospheres, liposomes and microemulsions.
- 25
5. The composition of matter of claim 1 wherein the endothelial surface determinants are defined further as characteristically being enhanced in quantity when proximal to tissue lesions.
- 30
6. The composition of matter of claim 5 wherein the endothelial surface determinants comprise Factor VIII antigen, interleukin I receptor, endothelial
- 35

thrombomodulin, endothelial tissue factor, subendothelial tissue moieties, fibrin D-D dimer and GP 2b/3a glycoprotein complex.

5

7. The composition of matter of claim 1 wherein the multivalent binding agent is heparin, a heparin fragment or Ulex Europaeus I lectin.

10

8. The composition of matter of claim 6 wherein the subendothelial tissue moieties are laminin, type IV collagen, fibronectin or a fibronectin fragment chemotactic for monocytes.

15

9. The composition of matter of claim 1 wherein the multivalent binding agent binds to vascular endothelium via endothelial surface receptors, surface enzymes, substances which coat the endothelial surface or substances which immediately underlie the endothelium and may be deposited, exposed or altered in normal vascular endothelium or proximal to foci of tissue or endothelial disease.

25

10. The composition of matter of claim 1 defined further wherein binding of a sample thereof to endothelia produces an induction of the endothelia to totally or partially envelop bound sample in less than 10 to 15 minutes.

30

11. The composition of matter of claim 1 defined further wherein interaction of a sample thereof with endothelia produces an induction of the endothelia to undergo transient separation or opening, thereby exposing

35

subendothelial determinants for which the composition of matter has binding affinity.

5 12. The composition of matter of claim 1 defined further
wherein interaction of a sample thereof with endothelia
produces an induction of total or partial sequestration of
the drug or diagnostic agent at an early time when it
still resides in or protrudes into an associated vascular
10 lumen.

13. The composition of matter of claim 1 defined further
wherein interaction of a sample thereof with endothelia
15 produces an acceleration of transport of the sample across
at least one of associated vascular endothelium and
subendothelial structures into a proximal tissue
compartment.

20

14. The composition of matter of claim 1 defined further
wherein interaction of a sample thereof with endothelia
results in improvement of the efficiency with which an
associated drug or diagnostic agent migrates across the
25 endothelia and associated structures such that a reduced
total dose of drug or diagnostic agent may be administered
to obtain effects comparable to a significantly higher
dose of free drug or diagnostic agent.

30

15. The composition of matter of claim 14 defined further
wherein interaction of a sample thereof with endothelia
produces an induction of total or partial sequestration of
the drug or diagnostic carrier at an early time when it
35 still resides in or protrudes into an associated vascular
lumen.

16. The composition of matter of claim 1 defined further as being a microsphere.

5 17. The composition of matter of claim 16 wherein the microsphere is between 0.2 and 250um in diameter.

18. The composition of matter of claim 16 in which the
10 microsphere comprises a matrix.

19. The composition of matter of claim 18 in which the
15 matrix is a carbohydrate.

20. The composition of matter of claim 18 in which the
matrix is heparin.

20 21. The composition of matter of claim 20 in which the drug or diagnostic agent is amphotericin B.

25 22. The composition of matter of claim 21 in which the amphotericin B is a cyclodextrin complex.

23. The composition of matter of claim 21 wherein the
30 amphotericin B is in a controlled-release form.

24. The composition of matter of claim 23 wherein the
35 amphotericin B is within internally entrapped micelles of pluronic F68 block copolymer, polyoxypropylene-polyoxyethylene.

25. The composition of matter of claim 18 in which the matrix is dextran.
- 5 26. The composition of matter of claim 25 wherein the matrix is coated with the multivalent binding agent heparin.
- 10 27. The composition of matter of claim 26 wherein the heparin is about 10% (w/w).
- 15 28. The composition of matter of claim 18 wherein the microsphere matrix is dextran, the matrix is coated with the multivalent binding agent heparin at about 10% (w/w), and the microsphere matrix entraps the drug, amphotericin B in a controlled-release form as a cyclodextrin complex.
- 20 29. The composition of matter of claim 18 in which the microsphere matrix is dextran, the matrix is coated with multivalent binding agent heparin at about 10% (w/w), and the microsphere matrix entraps the drug, amphotericin B in a controlled-release form within internally entrapped micelles of pluronic F68 block copolymer, polyoxypropylene-polyoxyethylene.
- 25 30. The composition of matter of claim 18 in which the microsphere matrix is a carbohydrate and the multivalent binding agent is an exposed or covert lectin capable of binding endothelial surface determinants, enzymes, epi-endothelial or subendothelial substances.

31. A composition of matter comprising a carrier having a surface, at least two molecules of drug or diagnostic agent contained by the carrier, a multivalent binding agent specific for endothelial determinants, at least a
5 portion of said binding agent being attached to the surface of said carrier and a removable coating which renders the multivalent binding agent unexposed to external contacts.

10

32. The composition of matter of claim 31 wherein the removable coating is subjected to removal by a triggering event.

15

33. The composition of matter of claim 31 wherein the triggering event is lowered pH, temperature alteration, contact with normal endothelia, contact with abnormal endothelia, altered enzyme levels or physical changes
20 induced by application of external forces such as radiofrequency, ultrasound, magnetism or electricity.

34. The composition of matter of claim 31 in which the
25 multivalent binding agent is a lectin with affinity for endothelial, epi- or subendothelial determinants.

35. The composition of matter of claim 34 in which the
30 lectin is Ulex Europaeus I lectin and the removable coating is fucose.

36. The composition of matter of claim 34 in which the
35 endothelial (epi- or subendothelial) binding site is

conferred by Ulex Europaeus I lectin and the removable coating is fucosyl-albumin or albumin-fucosylamine.

- 5 37. The composition of matter of claim 1 or claim 31 in which the multivalent binding agent is an antibody with affinity for endothelial or subendothelial binding sites.
- 10 38. The composition of matter of claim 1 or claim 31 wherein the multivalent binding agent is a substrate for an endothelial or epi-endothelial enzyme.
- 15 39. The composition of matter of claim 38 in which the multivalent binding agent is a peptide.
- 20 40. The composition of matter of claim 38 in which the multivalent binding agent is benzoyl-phenylalanyl-alanylproline.
- 25 41. The composition of matter of claim 40 in which the benzoyl-phenylalanyl-alanylproline has a substrate affinity for endothelial angiotensin converting enzyme.
- 30 42. The composition of matter of claim 1 or claim 31 in which the multivalent binding agent is a binding inhibitor of the endothelial enzyme, angiotensin converting enzyme.
- 35 43. The composition of matter of claim 1 or claim 31 in which the multivalent binding agent produces adhesion to

basement membrane structures on an abluminal side of the endothelium.

5 44. The composition of matter of claim 1 or claim 31 in which the drug or diagnostic agent and the multivalent binding agent are the same and comprise a polymeric molecule with two or more binding sites for endothelial, epi-endothelial, or subendothelial determinants.

10

45. The composition of matter of claim 1 or claim 31 in which the drug or diagnostic agent and the multivalent binding agent are the same and comprise a molecular
15 microaggregate of 1 to 200 nanometers in molecular diameter.

20 46. The composition of matter of claim 1 or claim 31 in which the drug or diagnostic agent and the multivalent binding agent are the same and comprise a molecular microaggregate of heparin of about 100 to 200 nanometers in molecular diameter.

25

47. The composition of matter of claim 1 or claim 31 are in a pharmaceutically acceptable solution suitable for intravascular or other parenteral injection.

30

48. A method of diagnosis or treatment of biological lesions, the method comprising the steps of:

35 preparing a composition of matter a carrier having a surface, at least two molecules of drug or diagnostic agent contained by the carrier and a

multivalent binding agent specific for endothelial surface determinants, at least a portion of said binding agent being attached to the surface of said carrier;

5

containing said composition of matter in a pharmaceutically acceptable carrier; and

10

administering the composition of matter in the pharmaceutically acceptable carrier to an animal.

49. The method of claim 48 wherein the multivalent binding agents are selected for particular targeted sites, most such as the endothelia.

50. The method of claim 48 wherein the drug or diagnostic agent is selected according to the particular lesion being treated or the diagnostic method being utilized.

51. The method of claim 48 wherein the carrier is a natural or synthetic polymer.

52. The composition of matter of claim 23 wherein the amphotericin B is within internally entrapped micelles of pluronic F108 block copolymer, polyoxypropylene-polyoxyethylene.

53. The composition of matter of claim 1 defined further as being a nanosphere.

35

54. The composition of matter of claim 53 wherein the nanosphere is between 1 and 999 nm in diameter.

5 55. The composition of matter of claim 54 wherein the nanosphere comprises a matrix.

56. The composition of matter of claim 55 in which the
10 matrix is a carbohydrate.

57. The composition of matter of claim 56 in which the matrix is heparin.

15

58. The composition of matter of claim 57 in which the drug or diagnostic agent is amphotericin B.

20

59. The composition of matter of claim 58 in which the amphotericin B is in a controlled release form.

25 60. The composition of matter of claim 59 wherein the amphotericin B is within internally entrapped micelles of Fl08 pluronic block copolymer, polyoxypropylene-polyoxyethylene.

30

61. The composition of matter of claim 59 wherein the amphotericin B is within internally entrapped as a cyclodextrin complex.

35

62. A composition of matter comprising a carrier having a surface, at least two molecules of drug or diagnostic agent contained by the carrier, and a multivalent binding agent specific for or complementary to epithelial surface determinants, at least a portion of said binding agent being attached to the surface of said carrier.

63. The composition of matter of claim 1 or claim 62 defined further as being a complex formed between the carrier and a drug or diagnostic agent.

64. The composition of matter of claim 63 wherein the complex is formed by paired-ion charge interactions or hydrophobic interactions between the carrier and drug.

65. The composition of matter of claim 62 wherein the carrier substance is a single or multimolecular layer and whereby the carrier forms at least a portion of the external surface and may also internally stabilize the drug or diagnostic agent.

66. The composition of matter of claim 63 wherein the carrier substance is heparin and the drug is cis-platin and the carrier and drug are formulated as an emulsion.

67. The composition of matter of claim 63 wherein the carrier substance is heparin at about 0.2 to 55% (w/w) and the drug is cis-platin at about 45 to 99.8% (w/w), the cis-platin is contained in aqueous media at a concentration of about 1 to 20mg/ml, and the resulting heparin-cis-platin solution or suspension is further

stabilized as an emulsion by high-pressure homogenization or sonification.

5 68. The composition of matter of claim 63 wherein the carrier substance is a lipid emulsion of vegetable oil and surface phospholipids, into the surface of which has been inserted a paired-ion complex of heparin and aliphatic side chains, and within the lipid emulsion of which has
10 been entrapped the drug amphotericin B.

69. The composition of matter of claim 68 wherein the paired ion complex of heparin and aliphatic side chains,
15 vegetable oil, phospholipids and amphotericin B components are further stabilized by high pressure homogenization or sonification.

20 70. The composition of matter of claim 1 or claim 62 wherein the carrier is a molecular complex which has a Stokes radius of between approximately 0.02 and 3 nanometers.

25 71. The composition of matter of claim 1 or claim 62 wherein the carrier is a particle or molecular aggregate which has a diameter of between about 1 nanometer and 250 micrometers.

30 72. The composition of matter of claim 62 wherein the binding agent is defined further as bioadhering to epithelial surface determinants and inducing envelopment
35 of the carrier by epithelial cells and transfer across said cells into proximal tissues.

73. The composition of matter of claim 62 wherein the carrier comprises one or more of: macromolecules, microaggregates, macroaggregates, microparticles, microspheres, nanospheres, liposomes, nanoemulsions, 5 microemulsions, hollow vesicles, intact cells, sperm, egg, modified living cells, bacteria, yeast, and carriers derived therefrom.

10 74. The composition of matter of claim 62 wherein the epithelial surface determinants are defined further as characteristically being enhanced in quantity or availability when located proximal to pathologic tissue lesions.

15

75. The composition of matter of claim 74 wherein the epithelial surface determinants comprise at least one of heparin sulfate, glycoasminoglycans complementary to 20 heparin, components of cellular and cellularly derived mucous, components of cellular and cellularly derived carbohydrates and oligosaccharides, glycoproteins, glycolipids, gangliosides, and receptor proteins, and fibrin D-D dimer, glycoprotein 2b/3a glycoprotein complex, 25 and subepithelial tissue moieties.

76. The composition of matter of claim 62 wherein the multivalent binding agent is heparin, a heparin fragment 30 or a natural, semisynthetic or synthetic heparin derivative.

77. The composition of matter of claim 62 wherein the 35 multivalent binding agent is dermatan sulfate, a dermatan

sulfate fragment or a natural, semisynthetic or synthetic derivative thereof.

5 78. The composition of matter of claim 75 wherein the subepithelial tissue moieties are at least one of fibronectin, fibronectin fragments, RGDS peptide sequence of fibronectin, type IV collagen, subregions of type IV collagen, heparin-binding sequences of type IV collagen,
10 type I collagen, subregions of type I collagen, laminin, subregions of laminin, heparin-binding subregions of laminin, laminin fragments, dermatan sulfate glycoaminoglycans, heparin-associating subregions of dermatan sulfate glycosaminoglycans, chondroitin sulfate
15 glycosaminoglycans and components of cellular and cellularly derived mucous.

20 79. The composition of matter of claim 62 wherein the multivalent binding agent binds to epithelia via epithelial surface receptors, surface enzymes, substances which immediately underlie the epithelia and may be deposited, exposed or altered in normal epithelium or proximal to foci of tissue or epithelial disease.

25

80. The composition of matter of claim 62 wherein binding of a sample thereof to epithelia produces an induction of the epithelia to totally or partially envelop the bound
30 sample in less than 10 to 15 minutes.

81. The composition of matter of claim 62 wherein interaction of a sample thereof with epithelia produces an
35 induction of the epithelia to undergo transient separation

or opening, thereby exposing subendothelial determinants for which the composition of matter has binding affinity.

5 82. The composition of matter of claim 62 wherein
interaction of a sample thereof with epithelia produces an
induction of total or partial sequestration of the drug or
diagnostic agent at an early time when it still resides in
or protrudes into the overlying extraepithelial space,
10 lumen, surface or cavity.

83. The composition of matter of claim 62 wherein
interaction of a sample thereof with epithelia produces an
15 acceleration of transport of the sample into and across
the associated epithelia and into at least one of
subepithelial structures and proximal tissue compartment.

20 84. The composition of matter of claim 62 wherein
interaction of a sample thereof with epithelia results in
improvement of the efficiency with which an associated
drug or diagnostic agent migrates across the epithelia and
associated structures such that a reduced total dose of
25 drug or diagnostic agent may be administered to obtain
effects comparable to a significantly higher dose of
conventionally administered drug or diagnostic agent.

30 85. The composition of matter of claim 62 defined further
as being a microsphere or nanosphere.

86. The composition of matter of claim 85 in which the
35 microsphere is between 1 and 250um in diameter.

87. The composition of matter of claim 85 in which the nanosphere is between 1 and 999 nm in diameter.

5 88. The composition of matter of claim 85 in which the microsphere or nanosphere comprises a matrix.

89. The composition of matter of claim 88 in which the
10 matrix is a carbohydrate.

90. The composition of matter of claim 88 in which the
15 matrix is heparin.

91. The composition of matter of claim 90, in which the
20 drug or diagnostic agent is amphotericin B.

92. The composition of matter of claim 91 wherein the
25 amphotericin B is in a controlled-release form.

93. The composition of matter of claim 94 wherein the
30 amphotericin B is within internally entrapped micelles of pluronic F108 block copolymer, polyoxypropylene-polyoxyethylene.

94. The composition of matter of claim 92 wherein the
35 amphotericin B is within internally entrapped micelles of amphotericin B-deoxycholate.

95. The composition of matter of claim 92 wherein the amphotericin B is within internally entrapped complexes of amphotericin B-cyclodextrin.

5

96. The composition of matter of claim 88 in which the matrix is dextran, starch, or a derivative thereof.

10 97. The composition of matter of claim 88 in which the matrix is dextran.

98. The composition of matter of claim 97 in which the
15 matrix is coated with the multivalent binding agent, heparin.

99. The composition of matter of claim 98 wherein the
20 heparin is about 0.2-10% (w/w).

100. The composition of matter of claim 88 wherein the matrix is dextran, the matrix is coated with the
25 multivalent binding agent, heparin at about 0.2-10% (w/w), and the microsphere matrix entraps the drug, amphotericin B in a controlled-release form as internally entrapped complexes of cyclodextrin.

30

101. The composition of matter of claim 88 wherein the matrix is dextran, the matrix is coated with the multivalent binding agent, heparin at about 0.2-10% (w/w), and the microsphere matrix entraps the drug, amphotericin
35 B in a controlled-release form as internally entrapped micelles of pluronic F108 block copolymer.

102. The composition of matter of claim 88, in which the matrix is a carbohydrate and the multivalent binding agent is an exposed or covert lectin capable of binding epithelial surface determinants, receptors, enzymes,
5 complementary biochemical substituents, epi-endothelial or subendothelial substances.

103. The composition of matter of any of claims 31 through 10
39, and 42 through 47, in which the target cells which bind the compositions of matter described therein, include epithelia as well as endothelia.

15 104. The composition of matter of claim 62 in which the carrier has a molecular Stokes radius of between about 0.01 and about 3 nm.

20 105. The composition of matter of claim 62 in which the complex comprises a microaggregate or macroaggregate having a size between approximately 0.02 nanometers and 100 micrometers.

25

106. The composition of matter of claim 85 in which the matrix is albumin.

30 107. The composition of matter of claim 106 in which the drug or diagnostic agent is amphotericin B.

108. The composition of matter of claim 107 wherein the
35 amphotericin B is in a controlled-release form.

109. The composition of matter of claim 108 wherein the amphotericin B is within internally entrapped micells of pluronic F108 block copolymer, polyoxypropylene-polyoxyethylene.

5

110. The composition of matter of claim 108 wherein the amphotericin B is within internally entrapped micelles of amphotericin B-deoxycholate.

10

111. The composition of matter of claim 108 wherein the amphotericin B is within internally entrapped complexes of amphotericin B-cyclodextrin.

15

112. The composition of matter of claim 85 wherein the diagnostic tracer agent is the iron oxide, Fe_3O_4 .

20

113. The composition of matter of claim 85 in which the matrix and surface coating are heparin, the entrapped diagnostic tracer is iron oxide, Fe_3O_4 , and the entrapment formulation is stabilized by heating.

25

114. The composition of matter of claim 85, in which the matrix is albumin, the entrapped diagnostic tracer is iron oxide, Fe_3O_4 , the surface coating is heparin, and the entrapment formulation is stabilized by heating

30

115. The composition of matter of claim 85, in which the matrix is albumin, the entrapped diagnostic tracer is iron oxide, Fe_3O_4 , the entrapment formulation is stabilized by

35

heating and a paired-ion complex of heparin and aliphatic side chains is added as a surface material.

5 116. The composition of matter of claim 1 or claim 62, in which the matrix is albumin, the entrapped therapeutic agent is recombinant ala-125-interleukin 2, the entrapment formulation is stabilized by chemical-crosslinking with formaldehyde, and heparin is present as a surface
10 material.

117. The composition of matter of claim 1 or claim 62, in which the matrix is albumin, the entrapped therapeutic
15 agent is recombinant ala-125-interleukin 2, the entrapment formulation is stabilized by chemical-crosslinking with formaldehyde, and a paired-ion complex of heparin and aliphatic side chains is added as a surface material.

20

118. The method of claim 48, further defined as pertaining to uptake of carrier and drug or diagnostic agent by or binding to endothelial or epithelial uptake mechanisms.

25

119. The method of claim 48, in which the carrier of drug or diagnostic agent is administered by intravenous route, for the purpose of obtaining high-efficiency uptake in the lungs.

30

120. The method of claim 48, in which the carrier of drug or diagnostic agent is administered by selected arterial perfusion, for the purpose of obtaining high-efficiency
35 uptake in proximal target organs, tissues or tissue lesions.

121. The method of claim 48, in which the carrier of drug or diagnostic agent is administered by intravenous injection and for the purpose of obtaining semiselective, medium-efficiency uptake in tissue lesions located at
5 widely distributed systemic sites.

122. The method of claim 118, in which the carrier of drug or diagnostic agent is administered by a route which
10 brings it directly into contact with epithelia.

123. The method of claim 122, in which the carrier of drug or diagnostic agent is intratracheally administered by
15 fluid installation or aerosolization in order to obtain high-efficiency localization in lung tissues.

124. The method of claim 122 in which the carrier of drug
20 or diagnostic agent is administered into the bladder.

125. The method of claim 122 in which the carrier of drug or diagnostic agent is administered into the
25 gastrointestinal tract.

126. The method of claim 125 in which the carrier of drug or diagnostic agent is administered into the
30 gastrointestinal tract by enteric installation.

127. The method of claim 125 in which the carrier of drug or diagnostic agent is administered into the
35 gastrointestinal tract by oral installation, wherein the carrier is enterically coated to protect it against

degradation in the stomach and to provide enhanced delivery to the small and large bowel.

5 128. The method of claim 125 in which the carrier of drug or diagnostic agent is administered into the gastrointestinal tract in order to obtain partial uptake across the bowel mucosa into the draining portal circulation and by these routes, secondarily into the
10 liver and systemic circulations.

129. The method of claim 128, in which sulfated or sulfonated detergents are emulsified with or covalently
15 conjugated to the carrier of drug or diagnostic agent, and are co-administered in order to obtain augmented uptake across the bowel mucosa into the portal and systemic circulations.

20

130. The method of claim 122 in which the carrier of drug or diagnostic agent is administered into a body cavity, lumen, space or surface, so as to enhance the localized or regional uptake efficiency, minimize toxicity, and reduce
25 the dose and wastage of drug or diagnostic agent.

131. The method of any of claim 48, and claims 118 through 130 in which administration of the carriers of drug or
30 diagnostic agent leads to improved site-specific localization of the drug or diagnostic agent by endothelial or epithelial cell uptake.

35 132. The methods of any of claim 48, and claims 118 through 130 in which administration of the carriers of

drug or diagnostic agent leads to improved percolation by the carrier or agent, into and through normal and lesional tissues, cells, and gel substances, thereby providing improved access to cells, microbes, and other target substances located within sequestered sites or within the draining regional capillaries and lymphatics, or providing improved and protracted localization of drug or diagnostic agent at these sites.

10

133. The composition of matter of claim 30, in which the microsphere matrix is dextran or starch and the multivalent binding agent is Ulex I europaeus agglutinin.

15

134. The composition of matter of claim 42 in which the multivalent binding agent is the angiotensin-converting-enzyme inhibitor, lisinopril.

20

135. The composition of matter of claim 42 in which the multivalent binding substance is a covalent albumin conjugate of the angiotensin-converting-enzyme inhibitor, lisinopril.

25

136. The composition of matter of claim 135 in which the multivalent binding substance and matrix substance are the same.

30

137. The methods of any of claims 48, 50, 51, and 118 through 132 in which the drug or diagnostic agent is a natural or synthetic polymer, which is coated with or complexed to a surface drug, enzyme, inhibitor, peptide, polypeptide, protein, glycoprotein, lectin, dextrin,

oligosaccharide, polysaccharide, carbohydrate,
glycosaminoglycan, sulfated or carboxylated
glycosaminoglycan, positively charged or amino-containing
carbohydrate, glycolipid, or ganglioside, antibody,
5 chimeric antibody, antibody fragment, and derivatives and
combinations thereof.

138. The methods of any of claims 48, 50, 51 and 118
10 through 132 in which the multivalent bioadhesive surface
material or complex which mediates endothelial or
epithelial binding, uptake and transport, is used in
combination with naturally hydrophilic carrier matrices,
including carbohydrates, oligosaccharides, dextrans,
15 sugars, heparin, heparan and dermatan sulfates, dextran,
starch, laminin, fibronectin, and living and modified
cells and microorganisms, small and macromolecular drugs,
and derivatives thereof.

20

139. The methods of any of claims 48, 50, 51 and 118
through 132 in which the multivalent bioadhesive surface
material or complex which mediates endothelial or
epithelial binding, uptake and transport, is used in
25 combination with naturally, partly or completely
hydrophobic carrier matrices, including albumins,
denatured albumins, lipid-in-water emulsions,
microemulsions and nanoemulsions, liposomes, cross-linked
or otherwise stabilized liposomes, polylactic acid,
30 polyglycolic acid and mixed polylactic-polyglycolic acids,
Types IV and I collagen, hydrophobic small and
macromolecular drugs, and derivatives thereof.

35 140. The composition of matter of claim 18 or claim 88 in
which the matrix is albumin.

141. The composition of matter of claim 140 in which the drug or diagnostic agent is amphotericin B.

5 142. The composition of matter of claim 141 in which the amphotericin B is in a controlled-release form.

143. The composition of matter of claim 142 in which the
10 amphotericin B is within internally entrapped complexes of cyclodextrin.

144. The composition of matter of claim 140 in which the
15 albumin matrix is coated with the multivalent binding agent, heparin.

145. The composition of matter of claim 144 wherein the
20 heparin is about 0.2-10% (w/w).

146. The composition of matter of claim 140 in which the
microsphere matrix is albumin, the matrix is coated with
25 the multivalent binding agent, heparin at about 0.2-10% (w/w), and the microsphere matrix entraps the drug amphotericin B in a controlled-release form as internally entrapped gamma cyclodextrin complexes.

30

147. The composition of matter of claim 140 in which the
microsphere matrix is albumin, the matrix is coated with
the multivalent binding agent, paired-ion complex of
heparin and aliphatic side chains at about 0.1-10% (w/w)
35 heparin, and the microsphere matrix entraps the drug

amphotericin B in a controlled-release form as internally entrapped gamma cyclodextrin complexes.

5 148. The composition of matter of claim 20 or claim 90 wherein the matrix and multivalent binding substance are both heparin and the matrix entraps the drug, cis-platin at about 40-99.8% (w/w) in a controlled-release form.

10

149. The composition of matter of claim 18 or claim 88 in which the matrix is dextran, the matrix is coated with the multivalent binding agent heparin at about 0.2-10% (w/w), and the matrix entraps the drug, cis-platin at about 40-
15 80% (w/w) in a controlled-release form.

150. The composition of matter of claim 18 or claim 88 in which the matrix is starch or a derivative thereof, the
20 matrix is coated with the multivalent binding agent, heparin at about 0.2-10% (w/w), and the matrix entraps the drug, cis-platin at about 40-80% (w/w) in a controlled-release form.

25

151. The composition of matter of claim 18 or claim 88 in which the matrix is albumin, the matrix is coated with the multivalent binding agent heparin at about 0.2-10% (w/w), and the matrix entraps the drug, cis-platin at about 40-
30 80% (w/w) in a controlled-release form.

152. The composition of matter of claim 18 or claim 88 in which the matrix is type IV collagen or a derivative
35 thereof, the matrix is coated with the multivalent binding agent, heparin at about 0.2-10% (w/w) and the matrix

entraps the drug, cis-platin at about 40-80% (w/w) in a controlled-release form.

5 153. The composition of matter of claim 18 or claim 88 in which the matrix is laminin, the matrix is coated with the multivalent binding agent, heparin at about 0.2-10% (w/w), and the matrix entraps the drug, cis-platin at about 40-80% (w/w) in a controlled-release form.

10

154. The composition of matter of claim 18 or claim 88 in which the matrix is a fibronectin-binding peptide or polypeptide, the matrix is coated with the multivalent
15 binding agent, heparin at about 0.2-10% (w/w), and the matrix entraps the drug, cis-platin at about 40-80% (w/w) in a controlled-release form.

20 155. The composition of matter of claim 18 or claim 88 in which the matrix is fibronectin, the matrix is coated with the multivalent binding agent heparin at about 0.2-10% (w/w), and the matrix entraps the drug, cis-platin at about 40-80% (w/w) in a controlled-release form.

25

156. The composition of matter of claim 18 or claim 88 in which the matrix is fibronectin, the matrix is coated with the multivalent binding agent heparin at about 0.2-10%
30 (w/w), and the matrix entraps the drug, amphotericin B at about 40-80% (w/w) in a controlled-release form.

FIG. 1



FIG. 2



FIG. 3



FIG. 4




FIG. 5



SUBSTITUTE SHEET

FIG. 6

